Brucellosis	other-disease
affects	O
almost	O
all	O
mammals	O
.	O

Those	O
who	O
are	O
obese	O
during	O
pregnancy	O
have	O
a	O
greater	O
risk	O
of	O
have	O
a	O
child	O
with	O
a	O
number	O
of	O
congenital	O
malformations	O
including	O
:	O
neural	other-disease
tube	other-disease
defects	other-disease
such	O
as	O
anencephaly	other-disease
and	O
spina	other-disease
bifida	other-disease
,	O
cardiovascular	other-disease
anomalies	other-disease
,	O
including	O
septal	other-disease
anomalies	other-disease
,	O
cleft	other-disease
lip	other-disease
and	O
palate	other-disease
,	O
anorectal	other-disease
malformation	other-disease
,	O
limb	other-disease
reduction	other-disease
anomalies	other-disease
,	O
and	O
hydrocephaly	other-disease
.	O

The	O
only	O
sign	O
of	O
BFNE	other-disease
are	O
seizures	O
,	O
generally	O
tonic-clonic	O
,	O
which	O
occur	O
within	O
the	O
first	O
week	O
of	O
life	O
.	O

The	O
expression	O
of	O
miR-181c	O
is	O
relevant	O
to	O
characterize	O
a	O
Breast	other-disease
cancer	other-disease
form	O
,	O
the	O
HER2/neu	O
.	O

Autism	O
spectrum	O
disorder	O
(	O
ASD	other-disease
)	O
is	O
a	O
range	O
of	O
complex	O
neurodevelopmental	O
disorders	O
,	O
characterized	O
by	O
social	O
impairments	O
,	O
communication	O
difficulties	O
,	O
and	O
restricted	O
,	O
repetitive	O
,	O
and	O
stereotyped	O
patterns	O
of	O
behavior	O
(	O
NINDS	O
,	O
2014	O
)	O
.	O

Polycythemia	other-disease
is	O
sometimes	O
called	O
erythrocytosis	other-disease
,	O
but	O
the	O
terms	O
are	O
not	O
synonymous	O
,	O
because	O
polycythemia	other-disease
refers	O
to	O
any	O
increase	O
in	O
red	O
blood	O
mass	O
(	O
due	O
to	O
an	O
erythrocytosis	O
or	O
not	O
)	O
,	O
whereas	O
erythrocytosis	other-disease
only	O
refers	O
to	O
a	O
documented	O
increase	O
of	O
red	O
cell	O
count	O
.	O

She	O
has	O
completed	O
murine	O
studies	O
looking	O
at	O
how	O
over	O
the	O
counter	O
Histamine	O
2	O
receptor	O
antagonists	O
,	O
such	O
as	O
Ranitidine	O
,	O
can	O
slow	O
or	O
reduce	O
the	O
growth	O
of	O
tumors	other-disease
such	O
as	O
those	O
in	O
breast	other-disease
cancer	other-disease
.	O

A	O
seminoma	other-disease
is	O
a	O
germ	O
cell	O
tumor	O
of	O
the	O
testicle	O
or	O
,	O
more	O
rarely	O
,	O
the	O
mediastinum	O
or	O
other	O
extra-gonadal	O
locations	O
.	O

Acephalgic	other-disease
migraine	other-disease
is	O
also	O
referred	O
to	O
as	O
amigrainous	other-disease
migraine	other-disease
,	O
ocular	other-disease
migraine	other-disease
,	O
ophthalmic	other-disease
migraine	other-disease
or	O
optical	other-disease
migraine	other-disease
,	O
last	O
three	O
being	O
misnomers	O
.	O

In	O
contrast	O
neighboring	O
Haiti	O
has	O
an	O
HIV	other-disease
/	O
AIDS	other-disease
rate	O
more	O
than	O
double	O
that	O
of	O
the	O
Dominican	O
Republic	O
.	O

People	O
can	O
develop	O
permanent	O
disabilities	O
including	O
``	O
cognitive	other-disease
deficits	other-disease
,	O
ataxia	other-disease
,	O
hemiparesis	other-disease
,	O
blindness	other-disease
,	O
deafness	other-disease
,	O
or	O
amputation	other-disease
following	other-disease
gangrene	other-disease
``	O
.	O

Men	O
who	O
present	O
with	O
this	O
complaint	O
may	O
have	O
Koro	other-disease
,	O
but	O
they	O
may	O
also	O
be	O
misinformed	O
about	O
normal	O
genital	O
size	O
.	O

S.	O
aureus	O
is	O
also	O
implicated	O
in	O
toxic	other-disease
shock	other-disease
syndrome	other-disease
;	O
during	O
the	O
1980s	O
some	O
tampons	O
allowed	O
the	O
rapid	O
growth	O
of	O
S.	O
aureus	O
,	O
which	O
released	O
toxins	O
that	O
were	O
absorbed	O
into	O
the	O
bloodstream	O
.	O

The	O
discoverers	O
of	O
nitromemantine	O
have	O
demonstrated	O
that	O
the	O
amyloid-β	O
peptide	O
associated	O
with	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
acts	O
as	O
an	O
agonist	O
at	O
α7	O
nicotinic	O
acetylcholine	O
receptors	O
,	O
chronic	O
overstimulation	O
of	O
which	O
then	O
results	O
in	O
uncontrolled	O
release	O
of	O
glutamate	O
,	O
and	O
consequent	O
excitotoxicity	O
.	O

Four	O
deaths	O
were	O
registered	O
in	O
the	O
official	O
adverse	O
event	O
register	O
,	O
and	O
while	O
in	O
only	O
two	O
cases	O
a	O
clear	O
causal	O
link	O
was	O
considered	O
to	O
be	O
in	O
place	O
,	O
two	O
other	O
cases	O
were	O
diagnosed	O
with	O
a	O
disease	O
which	O
in	O
scientific	O
peer-reviewed	O
articles	O
(	O
case	O
descriptions	O
)	O
have	O
been	O
mistakenly	O
first	O
made	O
,	O
and	O
afterward	O
have	O
been	O
noticed	O
to	O
be	O
disseminated	O
BCG	other-disease
infections	other-disease
.	O

Survivors	O
with	O
global	other-disease
aphasia	other-disease
may	O
have	O
great	O
difficulty	O
understanding	O
and	O
forming	O
words	O
and	O
sentences	O
,	O
and	O
generally	O
experience	O
a	O
great	O
deal	O
of	O
difficulty	O
when	O
trying	O
to	O
communicate	O
.	O

The	O
effectiveness	O
of	O
both	O
aspirin	O
and	O
clopidogrel	O
,	O
to	O
reduce	O
risk	O
of	O
cardiovascular	O
ischemic	O
events	O
in	O
people	O
with	O
symptomatic	O
PAD	other-disease
is	O
not	O
well	O
established	O
.	O

Marilee	O
Shapiro	O
Asher	O
(	O
November	O
17	O
,	O
1912	O
–	O
September	O
11	O
,	O
2020	O
)	O
was	O
an	O
American	O
sculptor	O
,	O
author	O
and	O
survivor	O
of	O
both	O
the	O
Spanish	other-disease
Flu	other-disease
and	O
COVID-19	other-disease
.	O

Arab	O
texts	O
from	O
this	O
period	O
contain	O
discussions	O
of	O
melancholia	other-disease
,	O
mania	other-disease
,	O
hallucinations	other-disease
,	O
delusions	other-disease
,	O
and	O
other	O
mental	O
disorders	O
.	O

These	O
abnormalities	O
are	O
also	O
seen	O
as	O
symptoms	O
of	O
schizophrenia	other-disease
.	O

The	O
unproven	O
health	O
benefits	O
attributed	O
to	O
yogurt	O
that	O
were	O
previously	O
posted	O
on	O
the	O
walls	O
of	O
Pinkberry	O
(	O
e.g.	O
,	O
cures	O
colon	other-disease
cancer	other-disease
,	O
fights	O
yeast	O
infections	O
)	O
have	O
been	O
removed	O
.	O

This	O
suggests	O
that	O
this	O
region	O
is	O
key	O
in	O
producing	O
confabulatory	O
responses	O
,	O
and	O
that	O
memory	O
deficit	O
is	O
important	O
but	O
not	O
necessary	O
in	O
confabulation	other-disease
.	O

Olfactory	O
dysfunction	O
(	O
loss	O
of	O
sense	O
of	O
smell	O
)	O
is	O
common	O
in	O
Parkinson	other-disease
’	O
s	O
disease	O
,	O
and	O
has	O
also	O
been	O
reported	O
to	O
occur	O
in	O
patients	O
with	O
essential	O
tremor	O
.	O

The	O
FMR1	O
knockout	O
rat	O
model	O
of	O
FXS	other-disease
exhibits	O
an	O
increased	O
ratio	O
of	O
slow	O
(	O
~25-50	O
Hz	O
)	O
to	O
fast	O
(	O
~55-100	O
Hz	O
)	O
gamma	O
waves	O
.	O

Buruli	other-disease
ulcers	other-disease
can	O
appear	O
anywhere	O
on	O
the	O
body	O
,	O
but	O
are	O
typically	O
on	O
the	O
limbs	O
.	O

Wallace	O
died	O
from	O
pneumonia	other-disease
and	O
sepsis	other-disease
on	O
October	O
25	O
,	O
2013	O
,	O
aged	O
70	O
,	O
a	O
week	O
before	O
her	O
71st	O
birthday	O
.	O

LET	other-disease
is	O
usually	O
found	O
on	O
sun-exposed	O
areas	O
of	O
the	O
body	O
.	O

In	O
2011	O
,	O
researchers	O
reported	O
the	O
discovery	O
of	O
an	O
antibody	O
effective	O
against	O
all	O
types	O
of	O
the	O
influenza	other-disease
A	other-disease
virus	O
.	O

Wasting	other-disease
-	O
Wasting	other-disease
is	O
when	O
a	O
child	O
's	O
weight	O
is	O
too	O
low	O
for	O
their	O
height	O
.	O

Combining	O
a	O
psychological	O
evaluation	O
with	O
data	O
from	O
magnetic	O
resonance	O
imaging	O
,	O
Kaien	O
’	O
s	O
work	O
found	O
a	O
link	O
between	O
Major	other-disease
Depressive	other-disease
Disorder	other-disease
(	O
MDD	other-disease
)	O
and	O
shrinkage	O
of	O
an	O
area	O
called	O
the	O
limbic	O
system	O
.	O
''	O

The	O
different	O
cutoffs	O
increased	O
the	O
reported	O
benefits	O
of	O
Vioxx	O
(	O
reduced	O
stomach	O
problems	O
)	O
relative	O
to	O
the	O
risks	O
(	O
increased	O
heart	other-disease
attacks	other-disease
)	O
.	O

Dwarfism	other-disease
was	O
not	O
seen	O
as	O
a	O
defect	O
in	O
ancient	O
Egypt	O
,	O
unlike	O
in	O
many	O
other	O
cultures	O
.	O

Mutations	O
in	O
the	O
gene	O
have	O
been	O
shown	O
to	O
cause	O
defects	O
in	O
the	O
protein	O
glycosylation	O
pathway	O
which	O
manifest	O
as	O
congenital	other-disease
disorder	other-disease
of	other-disease
glycosylation	other-disease
type	other-disease
Ia	other-disease
.	O

Albinism	other-disease
is	O
only	O
seen	O
in	O
about	O
1	O
of	O
every	O
1,800	O
birds	O
.	O

He	O
conceived	O
the	O
NAMES	O
Project	O
AIDS	other-disease
Memorial	O
Quilt	O
,	O
which	O
has	O
become	O
,	O
at	O
54	O
tons	O
,	O
the	O
world	O
's	O
largest	O
piece	O
of	O
community	O
folk	O
art	O
as	O
of	O
2016	O
.	O

Loss-of-function	O
mutations	O
in	O
the	O
STAT3	O
gene	O
result	O
in	O
Hyperimmunoglobulin	other-disease
E	other-disease
syndrome	O
,	O
associated	O
with	O
recurrent	O
infections	O
as	O
well	O
as	O
disordered	O
bone	O
and	O
tooth	O
development	O
.	O

Sabinas	other-disease
brittle	other-disease
hair	other-disease
syndrome	other-disease
,	O
also	O
called	O
Sabinas	other-disease
syndrome	other-disease
or	O
brittle	other-disease
hair-mental	other-disease
deficit	other-disease
syndrome	other-disease
,	O
is	O
an	O
autosomal	O
recessive	O
congenital	O
disorder	O
affecting	O
the	O
integumentary	O
system	O
.	O

Hyperglycemia	other-disease
may	O
be	O
present	O
,	O
as	O
glucose	O
consumption	O
by	O
cells	O
and	O
insulin	O
secretion	O
both	O
decrease	O
,	O
and	O
tissue	O
sensitivity	O
to	O
insulin	O
may	O
be	O
blunted	O
.	O

Mutations	O
in	O
this	O
gene	O
have	O
been	O
associated	O
with	O
various	O
forms	O
of	O
Charcot-Marie-Tooth	other-disease
Disease	other-disease
and	O
neuropathy	O
.	O

On	O
March	O
6	O
,	O
a	O
woman	O
from	O
Pinal	O
County	O
was	O
diagnosed	O
with	O
COVID-19	other-disease
.	O

Anterior	O
pituitary	O
function	O
must	O
be	O
normal	O
for	O
all	O
other	O
axes	O
in	O
CHH	other-disease
as	O
it	O
is	O
an	O
isolated	O
disorder	O
.	O

Lymphoedema	other-disease
may	O
develop	O
in	O
many	O
cases	O
accompanied	O
by	O
acral	O
thickening	O
of	O
the	O
skin	O
folds	O
,	O
hyperkeratosis	other-disease
and	O
papillomatosis	other-disease
.	O

Compartment	other-disease
syndrome	other-disease
is	O
a	O
condition	O
in	O
which	O
increased	O
pressure	O
within	O
one	O
of	O
the	O
body	O
's	O
anatomical	O
compartments	O
results	O
in	O
insufficient	O
blood	O
supply	O
to	O
tissue	O
within	O
that	O
space	O
.	O

One	O
week	O
later	O
,	O
4,500	O
Philadelphians	O
were	O
declared	O
dead	O
of	O
the	O
Spanish	other-disease
flu	other-disease
and	O
47,000	O
people	O
were	O
infected	O
.	O

Stuporous	O
catatonia	other-disease
is	O
characterized	O
by	O
immobility	O
during	O
which	O
patients	O
may	O
show	O
reduced	O
responsiveness	O
to	O
the	O
environment	O
(	O
stupor	O
)	O
,	O
rigid	O
poses	O
(	O
posturing	O
)	O
,	O
an	O
inability	O
to	O
speak	O
(	O
mutism	other-disease
)	O
,	O
and	O
waxy	O
flexibility	O
(	O
in	O
which	O
they	O
maintain	O
positions	O
after	O
being	O
placed	O
in	O
them	O
by	O
someone	O
else	O
)	O
.	O

The	O
key	O
components	O
of	O
a	O
detailed	O
history	O
include	O
age	O
of	O
onset	O
,	O
description	O
of	O
the	O
symptoms	O
including	O
rhythm	O
,	O
situations	O
that	O
commonly	O
result	O
in	O
the	O
symptoms	O
,	O
mode	O
of	O
onset	O
(	O
rapid	O
or	O
gradual	O
)	O
,	O
duration	O
of	O
symptoms	O
,	O
factors	O
that	O
relieve	O
symptoms	O
(	O
rest	O
,	O
Valsalva	O
)	O
,	O
positions	O
and	O
other	O
associated	O
symptoms	O
such	O
as	O
chest	other-disease
pain	other-disease
,	O
lightheadedness	other-disease
or	O
syncope	other-disease
.	O

This	O
is	O
a	O
sign	O
an	O
individual	O
has	O
prediabetes	other-disease
or	O
has	O
progressed	O
to	O
develop	O
type	other-disease
2	other-disease
diabetes	other-disease
.	O

Loss	O
of	O
LKB1	O
activity	O
is	O
associated	O
with	O
highly	O
aggressive	O
HER2	O
HER2+	other-disease
breast	other-disease
cancer	other-disease
.	O

CD	other-disease
is	O
differentiated	O
from	O
oppositional	other-disease
defiant	other-disease
disorder	other-disease
(	O
ODD	other-disease
)	O
in	O
that	O
children	O
with	O
ODD	other-disease
do	O
not	O
commit	O
aggressive	O
or	O
antisocial	O
acts	O
against	O
other	O
people	O
,	O
animals	O
,	O
and	O
property	O
,	O
though	O
many	O
children	O
diagnosed	O
with	O
ODD	other-disease
are	O
subsequently	O
rediagnosed	O
with	O
CD	other-disease
.	O

Amyloid	O
beta	O
is	O
considered	O
to	O
contribute	O
to	O
the	O
development	O
of	O
Alzheimer	other-disease
's	O
disease	O
,	O
and	O
there	O
exist	O
concerns	O
that	O
sacubitril	O
may	O
promote	O
the	O
development	O
of	O
Alzheimer	other-disease
's	O
disease	O
.	O

The	O
Panic	O
and	O
Agoraphobia	O
Scale	O
(	O
PAS	O
)	O
is	O
a	O
rating	O
scale	O
developed	O
for	O
measuring	O
severity	O
of	O
agoraphobia	other-disease
with	O
or	O
without	O
panic	O
attacks	O
.	O

Individuals	O
with	O
BENTA	other-disease
disease	O
have	O
polyclonal	O
B	O
cell	O
lymphocytosis	O
(	O
i.e	O
.	O

Polyhydramnios	other-disease
occurs	O
in	O
embryos	O
presenting	O
with	O
a	O
tracheoesophageal	O
fistula	O
as	O
the	O
liquid	O
produced	O
by	O
the	O
lungs	O
supposedly	O
pass	O
to	O
the	O
stomach	O
,	O
in	O
the	O
amniotic	O
fluid	O
.	O

Without	O
treatment	O
,	O
individuals	O
with	O
impetigo	other-disease
typically	O
get	O
better	O
within	O
three	O
weeks	O
.	O

RLS	other-disease
is	O
identified	O
by	O
the	O
strong	O
urge	O
to	O
move	O
and	O
is	O
a	O
dopamine-dependent	O
disorder	O
.	O

The	O
third	O
dose	O
of	O
the	O
MMR	other-disease
vaccine	O
was	O
associated	O
with	O
a	O
78.1	O
%	O
reduced	O
risk	O
of	O
infection	O
.	O

A	O
number	O
of	O
genetic	O
conditions	O
including	O
multiple	other-disease
endocrine	other-disease
neoplasia	other-disease
syndromes	O
also	O
increase	O
the	O
risk	O
.	O

Before	O
2013	O
,	O
the	O
subtypes	O
of	O
schizophrenia	other-disease
were	O
classified	O
as	O
paranoid	O
,	O
disorganized	O
,	O
catatonic	O
,	O
undifferentiated	O
,	O
and	O
residual	O
type	O
.	O

Young	O
’	O
s	O
discovery	O
of	O
doubletime	O
mutants	O
in	O
1998	O
was	O
soon	O
followed	O
by	O
the	O
2001	O
discovery	O
of	O
a	O
form	O
of	O
Familial	other-disease
Advanced	other-disease
Sleep	other-disease
Phase	other-disease
Syndrome	other-disease
(	O
FASPS	other-disease
)	O
in	O
humans	O
,	O
which	O
is	O
linked	O
to	O
an	O
hPer2	O
polymorphism	O
that	O
removes	O
a	O
serine	O
normally	O
phosphorylated	O
by	O
Casein	O
kinase	O
1	O
.	O

Coccidiosis	other-disease
typically	O
results	O
in	O
diarrhoea	other-disease
,	O
weight	O
loss	O
and	O
dehydration	O
.	O

Amantadine	O
was	O
first	O
used	O
for	O
the	O
treatment	O
of	O
influenza	other-disease
A	other-disease
.	O

Adult	O
patients	O
present	O
with	O
clinical	O
history	O
of	O
resistant	O
hypertension	other-disease
despite	O
typical	O
medical	O
therapy	O
and	O
lifestyle	O
changes	O
.	O

Nodular	other-disease
vasculitis	other-disease
is	O
a	O
skin	O
condition	O
characterized	O
by	O
small	O
,	O
tender	O
,	O
reddened	O
nodules	O
on	O
the	O
legs	O
,	O
mostly	O
on	O
the	O
calves	O
and	O
shins	O
.	O

The	O
arthropathy	O
can	O
,	O
therefore	O
,	O
be	O
an	O
early	O
clue	O
as	O
to	O
the	O
diagnosis	O
of	O
haemochromatosis	other-disease
.	O

A	O
physical	O
examination	O
that	O
is	O
positive	O
for	O
abdominal	O
pain	O
categorized	O
as	O
McBurney	O
’	O
s	O
point	O
tenderness	O
,	O
Von	O
Blumberg	O
's	O
sign	O
,	O
Rovsing	O
's	O
sign	O
,	O
Dunphy	O
's	O
sign	O
and	O
Psoas	O
sign	O
,	O
could	O
all	O
indicate	O
acute	O
appendicitis	other-disease
and	O
lead	O
to	O
misdiagnosis	O
.	O

In	O
polycythaemia	other-disease
vera	other-disease
,	O
the	O
most	O
common	O
side	O
effects	O
include	O
thrombocytopenia	other-disease
(	O
low	O
blood	O
platelet	O
counts	O
)	O
,	O
anaemia	other-disease
(	O
low	O
red	O
blood	O
cell	O
counts	O
)	O
,	O
bleeding	O
,	O
bruising	O
,	O
hypercholesterolaemia	other-disease
(	O
high	O
blood	O
cholesterol	O
levels	O
)	O
,	O
hypertriglyceridemia	other-disease
(	O
high	O
blood	O
fat	O
levels	O
)	O
,	O
dizziness	O
,	O
raised	O
liver	O
enzyme	O
levels	O
and	O
high	O
blood	O
pressure	O
.	O

Hyperpituitarism	other-disease
is	O
the	O
condition	O
where	O
the	O
pituitary	O
secretes	O
excessive	O
amounts	O
of	O
hormones	O
.	O

Myasthenia	other-disease
gravis	other-disease
is	O
an	O
autoimmune	O
disease	O
,	O
where	O
the	O
body	O
produces	O
antibodies	O
targeted	O
against	O
the	O
acetylcholine	O
receptor	O
on	O
the	O
postsynaptic	O
membrane	O
in	O
the	O
neuromuscular	O
junction	O
.	O

India	O
reports	O
over	O
50	O
%	O
of	O
the	O
world	O
's	O
leprosy	other-disease
cases	O
.	O

He	O
was	O
a	O
member	O
of	O
the	O
Association	O
of	O
American	O
Physicians	O
and	O
Surgeons	O
and	O
served	O
as	O
Committee	O
chairman	O
with	O
the	O
American	O
Gastroenterological	O
Association	O
and	O
on	O
the	O
National	O
Scientific	O
Advisory	O
Board	O
of	O
the	O
National	O
Foundation	O
for	O
Ileitis	other-disease
and	O
Colitis	other-disease
.	O

Paroxysmal	other-disease
nocturnal	other-disease
hemoglobinuria	other-disease
(	O
PNH	other-disease
)	O
is	O
a	O
rare	O
condition	O
resulting	O
from	O
acquired	O
alterations	O
in	O
the	O
``	O
PIGA	O
``	O
gene	O
,	O
which	O
plays	O
a	O
role	O
in	O
the	O
protection	O
of	O
blood	O
cells	O
from	O
the	O
complement	O
system	O
.	O

It	O
has	O
been	O
reported	O
that	O
diflunisal	other-disease
has	O
some	O
antibacterial	O
activity	O
``	O
in	O
vitro	O
``	O
against	O
``	O
Francisella	O
tularensis	O
``	O
live	O
vaccine	O
strain	O
(	O
LVS	O
)	O
.	O

Wani	O
was	O
diagnosed	O
with	O
Rokitansky	other-disease
Syndrome	other-disease
at	O
the	O
age	O
of	O
18	O
;	O
a	O
congenital	O
disorder	O
that	O
happens	O
to	O
one	O
in	O
every	O
4,500	O
to	O
5,000	O
women	O
.	O

LET	O
resolves	O
with	O
normal	O
skin	O
,	O
no	O
residual	O
scarring	O
,	O
no	O
hyperpigmentation	other-disease
or	O
hypopigmentation	other-disease
.	O

O	O
’	O
Laughlin	O
was	O
an	O
early	O
opponent	O
of	O
state	O
and	O
national	O
lockdowns	O
as	O
it	O
related	O
to	O
the	O
COVID-19	other-disease
pandemic	O
and	O
advocated	O
for	O
the	O
state	O
to	O
allow	O
visitors	O
to	O
return	O
to	O
nursing	O
homes	O
.	O

Sometimes	O
,	O
people	O
with	O
Barrett	other-disease
's	other-disease
esophagus	other-disease
have	O
no	O
heartburn	O
symptoms	O
at	O
all	O
.	O

In	O
2006	O
,	O
flood	O
damage	O
from	O
Tropical	other-disease
Storm	other-disease
Ernesto	other-disease
caused	O
the	O
earthen	O
retaining	O
dam	O
which	O
formed	O
the	O
lake	O
to	O
burst	O
and	O
empty	O
.	O

An	O
association	O
between	O
thyroid	other-disease
disease	other-disease
and	O
myasthenia	other-disease
gravis	other-disease
has	O
been	O
recognized	O
.	O

Café	other-disease
au	other-disease
lait	other-disease
spots	other-disease
are	O
often	O
harmless	O
but	O
may	O
be	O
associated	O
with	O
syndromes	O
such	O
as	O
neurofibromatosis	other-disease
type	other-disease
1	other-disease
and	O
McCune–Albright	other-disease
syndrome	O
.	O

In	O
May	O
2008	O
,	O
it	O
was	O
revealed	O
he	O
was	O
suffering	O
from	O
bone	O
cancer	other-disease
.	O

``	O
FLCN	O
``	O
mutations	O
and	O
lung	O
lesions	O
have	O
also	O
been	O
identified	O
in	O
familial	O
cases	O
of	O
pneumothorax	other-disease
where	O
other	O
features	O
of	O
Birt–Hogg–Dubé	other-disease
syndrome	other-disease
are	O
absent	O
.	O

Biotron	O
develops	O
novel	O
small	O
molecule	O
antiviral	O
therapeutics	O
targeting	O
Hepatitis	other-disease
C	other-disease
and	O
HIV	O
.	O

Most	O
people	O
with	O
CAD	other-disease
have	O
symptoms	O
of	O
hemolytic	other-disease
anemia	other-disease
(	O
destruction	O
of	O
red	O
blood	O
cells	O
,	O
causing	O
low	O
levels	O
of	O
red	O
blood	O
cells	O
)	O
.	O

Mann	O
thought	O
Nakajima	O
was	O
not	O
aggressive	O
enough	O
in	O
his	O
approach	O
against	O
AIDS	other-disease
.	O

Huntington	other-disease
's	other-disease
disease	other-disease
occurs	O
when	O
the	O
cytosolic	O
protein	O
Huntingtin	O
(	O
Htt	O
)	O
has	O
an	O
additional	O
35	O
glutamine	O
residues	O
added	O
to	O
its	O
amino	O
terminal	O
region	O
.	O

The	O
BSGT	O
is	O
used	O
for	O
patients	O
with	O
strabismus	other-disease
to	O
test	O
for	O
suppression	O
,	O
normal	O
retinal	O
correspondence	O
or	O
abnormal	O
retinal	O
correspondence	O
,	O
particularly	O
in	O
cases	O
of	O
manifest	O
strabismus	O
.	O

False	other-disease
memory	other-disease
syndrome	other-disease
is	O
a	O
condition	O
in	O
which	O
a	O
person	O
's	O
identity	O
and	O
interpersonal	O
relationships	O
center	O
on	O
a	O
memory	O
of	O
a	O
traumatic	O
experience	O
that	O
is	O
objectively	O
false	O
but	O
that	O
the	O
person	O
strongly	O
believes	O
occurred	O
.	O

Kallmann	other-disease
syndrome	other-disease
can	O
also	O
be	O
shown	O
through	O
MRI	O
imaging	O
with	O
irregular	O
morphology	O
or	O
aplasia	O
of	O
the	O
olfactory	O
bulb	O
and	O
olfactory	O
sulci	O
.	O

Radiation	O
exposure	O
increases	O
the	O
risk	O
of	O
primary	other-disease
hyperparathyroidism	other-disease
.	O

Myalgia	other-disease
(	O
muscular	O
pain	O
)	O
and	O
arthralgia	other-disease
(	O
joint	O
pain	O
)	O
are	O
rare	O
side	O
effects	O
.	O

Many	O
patients	O
with	O
a	O
foramen	other-disease
secundum	other-disease
that	O
persists	O
into	O
adulthood	O
will	O
remain	O
asymptomatic	O
throughout	O
their	O
lives	O
.	O

Additionally	O
,	O
they	O
may	O
be	O
suffering	O
from	O
penile	other-disease
dysmorphophobia	other-disease
.	O

LMNA	other-disease
and	O
PLN	other-disease
mutation	O
carriers	O
showed	O
a	O
high	O
prevalence	O
of	O
cardiac	O
transplantation	O
and	O
ventricular	O
arrhythmia	O
.	O

Large	O
,	O
swollen	O
conchae	O
,	O
often	O
referred	O
to	O
clinically	O
as	O
turbinates	O
,	O
may	O
lead	O
to	O
blockage	O
of	O
nasal	other-disease
breathing	other-disease
.	O

The	O
search	O
for	O
a	O
lazaret	O
site	O
in	O
northern	O
Queensland	O
followed	O
a	O
succession	O
of	O
other	O
attempts	O
to	O
segregate	O
Hansen	other-disease
's	other-disease
disease	other-disease
patients	O
.	O

These	O
compounds	O
are	O
therefore	O
thought	O
to	O
work	O
best	O
on	O
tumors	other-disease
that	O
contain	O
normal	O
or	O
``	O
wild-type	O
''	O
p53	O
.	O

In	O
Koro	other-disease
,	O
a	O
patient	O
is	O
overcome	O
with	O
the	O
belief	O
that	O
his	O
penis	O
is	O
actively	O
shrinking	O
,	O
and	O
it	O
may	O
be	O
in	O
imminent	O
danger	O
of	O
disappearing	O
.	O

Electrolyte	O
imbalances	O
remain	O
the	O
same	O
,	O
while	O
in	O
severe	O
cases	O
symptoms	O
can	O
advance	O
to	O
amino	other-disease
aciduria	other-disease
and	O
hyperammonemia	other-disease
.	O

Sickle-cell	other-disease
anemia	other-disease
is	O
associated	O
with	O
altered	O
average	O
vessel	O
diameter	O
.	O

A	O
child	O
between	O
12-14	O
is	O
considered	O
to	O
have	O
Anemia	other-disease
if	O
they	O
have	O
less	O
than	O
120g/L	O
of	O
hemoglobin	O
in	O
their	O
blood	O
.	O

Titers	O
to	O
GM1	other-disease
in	O
other	O
diseases	O
(	O
rheumatoid	other-disease
arthritis	other-disease
,	O
primary	other-disease
Sjögren	other-disease
's	other-disease
syndrome	other-disease
and	O
systemic	other-disease
lupus	other-disease
erythematosus	other-disease
)	O
was	O
also	O
elevated	O
.	O

There	O
are	O
criticisms	O
within	O
the	O
scientific	O
community	O
about	O
directing	O
resources	O
to	O
repurposing	O
drugs	O
specifically	O
developed	O
for	O
HIV	other-disease
/	O
AIDS	other-disease
because	O
such	O
drugs	O
are	O
unlikely	O
to	O
be	O
effective	O
against	O
a	O
virus	O
lacking	O
the	O
specific	O
HIV-1	other-disease
protease	O
they	O
target	O
.	O

A	O
particular	O
group	O
of	O
physical	O
features	O
,	O
called	O
the	O
Pierre	other-disease
Robin	other-disease
sequence	O
,	O
is	O
common	O
in	O
children	O
with	O
Stickler	other-disease
syndrome	O
.	O

Gene	O
duplication	O
of	O
PMP22	O
is	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
CMT	other-disease
where	O
the	O
overproduction	O
of	O
PMP22	O
results	O
in	O
defects	O
in	O
multiple	O
signalling	O
pathways	O
and	O
dysfunction	O
of	O
transcriptional	O
factors	O
like	O
KNOX20	O
,	O
SOX10	O
and	O
EGR2	O
.	O

In	O
general	O
,	O
homocysteine	O
is	O
an	O
amino	O
acid	O
and	O
metabolite	O
of	O
methionine	O
;	O
increased	O
levels	O
of	O
homocysteine	O
can	O
lead	O
to	O
homocystinuria	other-disease
(	O
see	O
section	O
Disease	O
Relevance	O
)	O
.	O

Bell	other-disease
's	other-disease
palsy	other-disease
is	O
characterized	O
by	O
a	O
one-sided	O
facial	O
droop	O
that	O
comes	O
on	O
within	O
72	O
hours	O
.	O

Early	O
latent	O
syphilis	other-disease
is	O
defined	O
by	O
the	O
World	O
Health	O
Organization	O
as	O
less	O
than	O
2	O
years	O
after	O
original	O
infection	O
.	O

In	O
2017	O
,	O
the	O
extended	O
release	O
formulation	O
was	O
approved	O
for	O
use	O
in	O
the	O
treatment	O
of	O
levodopa-induced	other-disease
dyskinesia	other-disease
.	O

The	O
Swine	other-disease
Flu	other-disease
(	O
also	O
known	O
as	O
H1N1	other-disease
)	O
epidemic	O
is	O
a	O
recent	O
disease	O
emerging	O
in	O
the	O
early	O
21st	O
century	O
.	O

Heparin-induced	other-disease
thrombocytopenia	other-disease
(	O
HIT	other-disease
)	O
is	O
due	O
to	O
an	O
immune	O
system	O
reaction	O
against	O
the	O
anticoagulant	O
drug	O
heparin	O
(	O
or	O
its	O
derivatives	O
)	O
.	O

Neuropathy	other-disease
disorders	other-disease
usually	O
have	O
onset	O
in	O
childhood	O
or	O
young	O
adulthood	O
.	O

For	O
example	O
,	O
some	O
diseases	O
like	O
Autoimmune	other-disease
GFAP	other-disease
Astrocytopathy	other-disease
or	O
variants	other-disease
of	other-disease
CIDP	other-disease
that	O
affects	O
the	O
CNS	other-disease
(	O
CIDP	O
is	O
the	O
chronic	O
counterpart	O
of	O
Guillain–Barré	other-disease
syndrome	other-disease
)	O
could	O
be	O
included	O
.	O

Neuromuscular	O
disease	O
can	O
be	O
caused	O
by	O
autoimmune	O
disorders	O
,	O
genetic	O
or	O
hereditary	O
disorders	O
such	O
as	O
channelopathies	other-disease
,	O
or	O
neurodegenerative	other-disease
diseases	other-disease
.	O

Smoldering	other-disease
Waldenström	other-disease
's	other-disease
macroglobulinemia	other-disease
is	O
diagnosed	O
in	O
asymptomatic	O
individuals	O
that	O
have	O
a	O
serum	O
IgM	O
level	O
30	O
gram/liter	O
and/or	O
a	O
bone	O
marrow	O
lymphoplasmacytoid	O
cell	O
infilatrate	O
&	O
gt	O
;	O
10	O
%	O
of	O
total	O
nucleated	O
cells	O
.	O

Additionally	O
,	O
many	O
people	O
who	O
have	O
autism	other-disease
have	O
issues	O
with	O
communication	O
and	O
some	O
have	O
limited	O
or	O
no	O
speech	O
.	O

After	O
an	O
Adderall	other-disease
binge	O
,	O
he	O
leaves	O
Ted	O
.	O

They	O
were	O
set	O
to	O
on	O
Northwestern	O
State	O
in	O
the	O
second	O
round	O
of	O
the	O
Southland	O
Tournament	O
until	O
the	O
tournament	O
was	O
cancelled	O
amid	O
the	O
COVID-19	other-disease
pandemic	O
.	O

These	O
levels	O
,	O
taken	O
as	O
a	O
set	O
,	O
can	O
be	O
rapidly	O
performed	O
to	O
indicate	O
several	O
common	O
acute	O
conditions	O
requiring	O
immediate	O
specific	O
medical	O
treatment	O
,	O
such	O
as	O
dehydration	other-disease
/	O
hypovolemia	other-disease
,	O
water	other-disease
intoxication	other-disease
(	O
which	O
can	O
present	O
with	O
similar	O
symptoms	O
to	O
dehydration	O
but	O
requires	O
the	O
opposite	O
treatment	O
)	O
,	O
diabetic	other-disease
shock	other-disease
(	O
either	O
ketoacidosis	other-disease
,	O
hyperglycemia	other-disease
or	O
hypoglycemia	other-disease
)	O
,	O
congestive	other-disease
heart	other-disease
failure	other-disease
,	O
kidney	other-disease
failure	other-disease
or	O
liver	other-disease
failure	other-disease
,	O
various	O
substance	O
overdoses	O
or	O
adverse	O
reactions	O
,	O
and	O
others	O
.	O

The	O
drug	O
was	O
prescribed	O
to	O
promote	O
muscle	O
regrowth	O
in	O
disorders	O
which	O
cause	O
involuntary	O
weight	O
loss	O
,	O
and	O
is	O
used	O
as	O
part	O
of	O
treatment	O
for	O
HIV	other-disease
/	O
AIDS	other-disease
.	O

For	O
example	O
,	O
in	O
delusional	other-disease
jealousy	other-disease
,	O
where	O
a	O
person	O
believes	O
that	O
his	O
partner	O
is	O
being	O
unfaithful	O
(	O
and	O
may	O
even	O
follow	O
her	O
into	O
the	O
bathroom	O
believing	O
her	O
to	O
be	O
seeing	O
her	O
lover	O
even	O
during	O
the	O
briefest	O
of	O
partings	O
)	O
,	O
it	O
may	O
actually	O
be	O
true	O
that	O
the	O
partner	O
is	O
having	O
sexual	O
relations	O
with	O
another	O
person	O
.	O

``	O
14th	O
century	O
''	O
:	O
after	O
the	O
Black	other-disease
Death	other-disease
(	O
1348–1350	O
)	O
Niall	O
O	O
’	O
Neill	O
refurbished	O
the	O
church	O
for	O
the	O
Franciscan	O
Order	O

Jenner	O
extracted	O
the	O
pus	O
of	O
one	O
of	O
the	O
lesions	O
formed	O
by	O
cowpox	other-disease
on	O
Nelmes	O
to	O
another	O
individual	O
who	O
had	O
never	O
had	O
smallpox	other-disease
,	O
an	O
eight-year-old	O
boy	O
called	O
James	O
Phipps	O
.	O

It	O
is	O
difficult	O
to	O
diagnose	O
mesenteric	other-disease
ischemia	other-disease
early	O
.	O

Another	O
type	O
of	O
work-related	O
asthma	other-disease
is	O
``	O
work-exacerbated	other-disease
asthma	other-disease
``	O
(	O
WEA	other-disease
)	O
which	O
is	O
asthma	other-disease
worsened	O
by	O
workplace	O
conditions	O
but	O
not	O
caused	O
by	O
it	O
.	O

They	O
often	O
cause	O
an	O
initial	O
flare-up	O
of	O
acne	other-disease
and	O
facial	O
flushing	O
and	O
can	O
cause	O
significant	O
skin	O
irritation	O
.	O

The	O
FDA	O
says	O
that	O
it	O
has	O
known	O
for	O
some	O
time	O
that	O
the	O
morcellators	O
could	O
spread	O
uterine	other-disease
cancer	other-disease
,	O
but	O
the	O
recent	O
attention	O
given	O
to	O
the	O
subject	O
because	O
of	O
the	O
death	O
of	O
Barbara	O
Leary	O
led	O
them	O
to	O
reopen	O
the	O
investigation	O
,	O
and	O
they	O
discovered	O
a	O
higher	O
risk	O
than	O
was	O
initially	O
reported	O
.	O

Fibromyalgia	other-disease
was	O
first	O
defined	O
in	O
1990	O
,	O
with	O
updated	O
criteria	O
in	O
2011	O
.	O

The	O
major	other-disease
(	other-disease
``	other-disease
type	other-disease
1	other-disease
''	other-disease
)	other-disease
thrombophilias	other-disease
are	O
rare	O
.	O

Expressive	other-disease
aphasia	other-disease
occurs	O
in	O
approximately	O
12	O
%	O
of	O
new	O
cases	O
of	O
aphasia	other-disease
caused	O
by	O
stroke	other-disease
.	O

The	O
cranial	other-disease
dysmorphisms	other-disease
associated	O
with	O
3C	other-disease
syndrome	other-disease
are	O
heterogeneous	O
and	O
include	O
a	O
degree	O
of	O
macrocephaly	O
,	O
a	O
large	O
anterior	O
fontanel	O
,	O
a	O
particularly	O
prominent	O
occiput	O
and	O
forehead	O
,	O
ocular	other-disease
hypertelorism	other-disease
(	O
wide-set	O
eyes	O
)	O
,	O
slanted	other-disease
palpebral	other-disease
fissures	other-disease
,	O
cleft	other-disease
palate	other-disease
,	O
a	O
depressed	O
nasal	O
bridge	O
,	O
cleft	O
palate	O
with	O
associated	O
bifid	O
uvula	O
,	O
low-set	O
ears	O
,	O
micrognathia	other-disease
(	O
an	O
abnormally	O
small	O
jaw	O
)	O
,	O
brachycephaly	other-disease
(	O
flattened	O
head	O
)	O
,	O
and	O
ocular	other-disease
coloboma	other-disease
.	O

Interestingly	O
,	O
whole-body	O
size	O
deficits	O
,	O
learning	O
defects	O
and	O
aberrant	O
RAS/ERK	O
signaling	O
are	O
also	O
key	O
features	O
of	O
the	O
NF1	other-disease
condition	O
in	O
humans	O
,	O
and	O
are	O
all	O
due	O
to	O
a	O
deregulation	O
of	O
the	O
Anaplastic	O
lymphoma	O
Kinase	O
ALK-NF1-RAS/ERK	O
signaling	O
pathway	O
in	O
flies	O
.	O

This	O
deficiency	O
can	O
lead	O
to	O
a	O
decrease	O
in	O
memory	O
,	O
judgement	O
and	O
the	O
ability	O
to	O
reason	O
,	O
of	O
which	O
are	O
key	O
symptoms	O
of	O
Alzheimer	other-disease
's	O
disease	O
.	O

Members	O
of	O
the	O
herpes	other-disease
virus	O
family	O
may	O
have	O
a	O
role	O
in	O
autism	other-disease
,	O
but	O
the	O
evidence	O
so	O
far	O
is	O
anecdotal	O
.	O

Cramp	other-disease
fasciculation	other-disease
syndrome	other-disease
(	O
CFS	other-disease
)	O
is	O
a	O
rare	O
peripheral	O
nerve	O
hyperexcitability	O
disorder	O
.	O

The	O
blepharospasm	other-disease
referred	O
to	O
here	O
is	O
officially	O
called	O
benign	other-disease
essential	other-disease
blepharospasm	other-disease
(	O
BEB	other-disease
)	O
to	O
distinguish	O
it	O
from	O
the	O
less	O
serious	O
secondary	O
blinking	O
disorders	O
.	O

They	O
discussed	O
organizing	O
a	O
new	O
campaign	O
to	O
retake	O
Missouri	O
,	O
but	O
Jackson	O
died	O
of	O
pneumonia	other-disease
and	O
stomach	other-disease
cancer	other-disease
before	O
such	O
actions	O
took	O
place	O
.	O

Its	O
Jenner	O
Building	O
,	O
a	O
former	O
smallpox	other-disease
hospital	O
,	O
is	O
a	O
Grade	O
II	O
listed	O
building	O
.	O

Loss	O
of	O
cancer	O
suppressor	O
genes	O
,	O
early	O
in	O
prostatic	other-disease
carcinogenesis	other-disease
,	O
have	O
been	O
localized	O
to	O
chromosomes	O
''	O
8p	O
``	O
,	O
``	O
10q	O
``	O
,	O
``	O
13q	O
``	O
,	O
and	O
``	O
16q	O
``	O
.	O

Thyroid	other-disease
cancer	other-disease
arising	O
in	O
the	O
background	O
of	O
radiation	O
is	O
often	O
multifocal	O
with	O
a	O
high	O
incidence	O
of	O
lymph	O
node	O
metastasis	O
and	O
has	O
a	O
poor	O
prognosis	O
.	O

This	O
GTPase	O
protein	O
domain	O
is	O
found	O
in	O
all	O
eukaryotic	O
tubulin	O
chains	O
,	O
as	O
well	O
as	O
the	O
bacterial	O
protein	O
TubZ	O
,	O
the	O
archaeal	O
protein	O
CetZ	O
,	O
and	O
the	O
FtsZ	O
protein	O
family	O
widespread	O
in	O
Bacteria	other-disease
and	O
Archaea	other-disease
.	O

In	O
a	O
type	O
of	O
send-up	O
of	O
his	O
award-winning	O
role	O
in	O
``	O
Summer	O
Snow	O
``	O
,	O
Chiao	O
played	O
the	O
part	O
of	O
the	O
Alzheimer	other-disease
disease	O
stricken	O
grandfather	O
of	O
Tung	O
Tzun	O
in	O
the	O
1996	O
film	O
``	O
Blind	O
Romance	O
``	O
.	O

In	O
2016	O
,	O
Edvardson	O
et	O
al.	O
,	O
identified	O
homozygosity	O
for	O
Arg204Trp	O
mutation	O
in	O
the	O
PLEKHG2	O
gene	O
in	O
the	O
patients	O
with	O
dystonia	other-disease
or	O
postnatal	other-disease
microcephaly	other-disease
.	O

HSP90	O
beta	O
has	O
been	O
identified	O
as	O
one	O
of	O
the	O
autoantigenic	O
biomarkers	O
and	O
targets	O
involved	O
in	O
human	other-disease
ovarian	other-disease
autoimmune	other-disease
disease	other-disease
leading	O
to	O
ovarian	O
failure	O
and	O
thereby	O
infertility	O
.	O

HACE	other-disease
was	O
first	O
described	O
by	O
a	O
medical	O
officer	O
stationed	O
in	O
Chile	O
in	O
1913	O
,	O
but	O
few	O
took	O
note	O
of	O
it	O
.	O

In	O
1973	O
,	O
the	O
FDA	O
approved	O
amantadine	O
for	O
use	O
in	O
the	O
treatment	O
of	O
Parkinson	other-disease
's	other-disease
disease	other-disease
.	O

For	O
a	O
diagnosis	O
of	O
sleep	other-disease
apnea	other-disease
,	O
more	O
than	O
five	O
episodes	O
per	O
hour	O
must	O
occur	O
.	O

PKC-ι	O
inhibition	O
or	O
knockdown	O
resulted	O
an	O
increase	O
E-cadherin	O
and	O
RhoA	O
levels	O
while	O
decreasing	O
total	O
Vimentin	O
,	O
phophorylated	O
Vimentin	O
(	O
S39	O
)	O
and	O
Par6	O
in	O
metastatic	O
melanoma	other-disease
cells	O
.	O

Reduced	O
HRV	O
has	O
been	O
shown	O
to	O
be	O
a	O
predictor	O
of	O
mortality	O
after	O
myocardial	other-disease
infarction	other-disease
although	O
others	O
have	O
shown	O
that	O
the	O
information	O
in	O
HRV	O
relevant	O
to	O
acute	O
myocardial	O
infarction	O
survival	O
is	O
fully	O
contained	O
in	O
the	O
mean	O
heart	O
rate	O
.	O

``	O
He	O
first	O
advanced	O
the	O
term	O
schizophrenia	other-disease
in	O
1908	O
in	O
a	O
paper	O
based	O
on	O
a	O
study	O
of	O
647	O
Burghölzli	O
patients	O
.	O

It	O
is	O
sometimes	O
associated	O
with	O
Marfan	other-disease
syndrome	other-disease
or	O
Loeys–Dietz	other-disease
syndrome	other-disease
,	O
but	O
may	O
also	O
result	O
from	O
Ehlers–Danlos	other-disease
syndrome	other-disease
,	O
bicuspid	O
aortic	O
valve	O
,	O
atherosclerosis	O
,	O
hypoplastic	O
left	O
heart	O
syndrome	O
,	O
syphilis	O
,	O
cystic	O
medial	O
necrosis	O
,	O
chest	O
injury	O
,	O
or	O
infective	O
endocarditis	O
.	O

In	O
Morquio	other-disease
syndrome	other-disease
,	O
the	O
specific	O
GAG	O
which	O
builds	O
up	O
in	O
the	O
body	O
is	O
called	O
keratan	O
sulfate	O
.	O

DIOS	other-disease
was	O
previously	O
known	O
as	O
meconium	other-disease
ileus	other-disease
equivalent	O
,	O
a	O
name	O
which	O
highlights	O
its	O
similarity	O
to	O
the	O
intestinal	other-disease
obstruction	other-disease
seen	O
in	O
newborn	O
infants	O
with	O
cystic	other-disease
fibrosis	other-disease
.	O

They	O
may	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
diplopia	other-disease
(	O
double	other-disease
vision	other-disease
)	O
,	O
asthenopia	other-disease
(	O
eye	O
strain	O
)	O
,	O
transient	other-disease
blurred	other-disease
vision	other-disease
,	O
difficulty	other-disease
sustaining	other-disease
near-visual	other-disease
function	other-disease
,	O
abnormal	other-disease
fatigue	other-disease
,	O

Clinical	O
manifestations	O
of	O
this	O
deficiency	O
can	O
include	O
myopathy	other-disease
,	O
cardiomyopathy	other-disease
,	O
episodes	O
of	O
coma	other-disease
,	O
and	O
hypoglycemia	other-disease
.	O

His	O
work	O
identified	O
a	O
link	O
between	O
cigarette	O
smoke	O
exposure	O
and	O
ACE2	O
over-expression	O
,	O
which	O
could	O
make	O
smokers	O
and	O
COPD	other-disease
patients	O
more	O
vulnerable	O
to	O
COVID19	other-disease
.	O

Type	other-disease
I	other-disease
antithrombin	other-disease
deficiency	other-disease
is	O
characterized	O
by	O
a	O
decrease	O
in	O
both	O
antithrombin	O
activity	O
and	O
antithrombin	O
concentration	O
in	O
the	O
blood	O
of	O
affected	O
individuals	O
.	O

Attention	other-disease
deficit	other-disease
hyperactivity	other-disease
disorder	other-disease
(	O
ADHD	other-disease
)	O
is	O
common	O
in	O
this	O
population	O
,	O
and	O
children	O
with	O
the	O
disorder	O
may	O
also	O
engage	O
in	O
substance	O
abuse	O
.	O

In	O
cases	O
of	O
homozygous	O
protein	O
C	O
deficiency	O
,	O
episodes	O
of	O
purpura	other-disease
fulminans	other-disease
and	O
other	O
thrombotic	O
events	O
are	O
recurrent	O
.	O

SMYD3	O
trimethylates	O
a	O
lysine	O
residue	O
on	O
MAP3K2	O
,	O
which	O
causes	O
crosstalk	O
into	O
the	O
MAP	O
kinase	O
signaling	O
pathway	O
in	O
Ras-driven	other-disease
cancers	other-disease
.	O

A	O
recombinant	O
,	O
slightly	O
modified	O
version	O
of	O
interleukin	O
1	O
receptor	O
antagonist	O
called	O
anakinra	O
is	O
used	O
in	O
the	O
treatment	O
of	O
rheumatoid	other-disease
arthritis	other-disease
,	O
an	O
autoimmune	O
disease	O
in	O
which	O
IL-1	O
plays	O
a	O
key	O
role	O
.	O

However	O
,	O
PCOS	other-disease
and	O
idiopathic	other-disease
hirsutism	other-disease
make	O
up	O
90	O
%	O
of	O
cases	O
.	O

People	O
with	O
this	O
form	O
of	O
agnosia	other-disease
have	O
difficulty	O
in	O
determining	O
and	O
identifying	O
the	O
motivational	O
and	O
emotional	O
significance	O
of	O
external	O
social	O
events	O
,	O
and	O
may	O
appear	O
emotionless	O
or	O
agnostic	O
(	O
uncertainty	O
or	O
general	O
indecisiveness	O
about	O
a	O
particular	O
thing	O
)	O
.	O

The	O
alpha-1	O
fraction	O
does	O
not	O
disappear	O
in	O
alpha	other-disease
1-antitrypsin	other-disease
deficiency	other-disease
,	O
however	O
,	O
because	O
other	O
proteins	O
,	O
including	O
alpha-lipoprotein	O
and	O
orosomucoid	O
,	O
also	O
migrate	O
there	O
.	O

In	O
addition	O
to	O
hemorrhagic	other-disease
cystitis	other-disease
,	O
temporary	O
hematuria	O
can	O
also	O
be	O
seen	O
in	O
bladder	O
infection	O
or	O
in	O
children	O
as	O
a	O
result	O
of	O
viral	O
infection	O
.	O

Conduct	other-disease
disorder	other-disease
(	O
CD	other-disease
)	O
is	O
a	O
disorder	O
diagnosed	O
in	O
childhood	O
that	O
parallels	O
the	O
characteristics	O
found	O
in	O
ASPD	other-disease
and	O
is	O
characterized	O
by	O
a	O
repetitive	O
and	O
persistent	O
pattern	O
of	O
behavior	O
in	O
which	O
the	O
basic	O
rights	O
of	O
others	O
or	O
major	O
age-appropriate	O
norms	O
are	O
violated	O
.	O

He	O
continued	O
to	O
conduct	O
research	O
and	O
publish	O
books	O
in	O
his	O
later	O
years	O
,	O
focusing	O
in	O
his	O
last	O
years	O
on	O
the	O
search	O
for	O
a	O
vaccine	O
against	O
HIV	other-disease
.	O

Described	O
as	O
an	O
``	O
instantly	O
recognizable	O
sad-faced	O
actor	O
''	O
,	O
Schiavelli	O
was	O
diagnosed	O
with	O
Marfan	other-disease
syndrome	other-disease
in	O
childhood	O
.	O

One	O
of	O
van	O
Riebeeck	O
's	O
tasks	O
include	O
planting	O
a	O
vineyard	O
,	O
falsely	O
believing	O
the	O
consumption	O
of	O
grapes	O
and	O
the	O
wine	O
produced	O
from	O
them	O
is	O
effective	O
in	O
avoiding	O
scurvy	other-disease
among	O
sailors	O
on	O
long	O
sea	O
voyages	O
.	O

The	O
use	O
of	O
prophylactic	O
antibiotics	O
in	O
ischemic	other-disease
colitis	other-disease
has	O
not	O
been	O
prospectively	O
evaluated	O
in	O
humans	O
,	O
but	O
many	O
authorities	O
recommend	O
their	O
use	O
based	O
on	O
the	O
animal	O
data	O
.	O

It	O
was	O
notable	O
for	O
featuring	O
the	O
first	O
use	O
of	O
fireworks	O
at	O
the	O
site	O
since	O
2008	O
and	O
for	O
being	O
held	O
amid	O
the	O
ongoing	O
COVID-19	other-disease
pandemic	O
.	O

It	O
is	O
used	O
in	O
the	O
treatment	O
of	O
vaginal	other-disease
candidiasis	other-disease
,	other-disease
for	O
the	O
protozoal	other-disease
infection	other-disease
trichomoniasis	other-disease
,	O
and	O
mixed	O
infections	O
.	O

SSRIs	O
,	O
topical	O
anesthetics	O
,	O
and	O
psychotherapy	O
are	O
commonly	O
used	O
to	O
treat	O
premature	other-disease
ejaculation	other-disease
.	O

Healthy	O
eating	O
is	O
a	O
key	O
factor	O
in	O
wellness	O
,	O
and	O
prevention	O
of	O
chronic	O
diseases	O
,	O
such	O
as	O
diabetes	other-disease
,	O
obesity	other-disease
,	O
heart	other-disease
disease	other-disease
and	O
cancer	O
.	O

In	O
August	O
2014	O
,	O
she	O
contracted	O
Dengue	other-disease
fever	other-disease
during	O
the	O
2014	O
Dengue	O
fever	O
outbreak	O
.	O

Hemoglobin	O
A2	O
may	O
be	O
increased	O
in	O
beta	other-disease
thalassemia	other-disease
or	O
in	O
people	O
who	O
are	O
heterozygous	O
for	O
the	O
beta	O
thalassemia	O
gene	O
.	O

Hypno-Hustler	other-disease
later	O
appeared	O
at	O
the	O
Vil-Anon	O
meeting	O
with	O
Armadillo	other-disease
,	O
Big	other-disease
Wheel	other-disease
,	O
Equinox	other-disease
,	O
Man-Bull	other-disease
,	O
and	O
Schizoid	other-disease
Man	other-disease
.	O

Xerostomia	other-disease
,	O
or	O
a	O
decrease	O
in	O
saliva	O
flow	O
,	O
can	O
be	O
a	O
side	O
effect	O
of	O
many	O
drugs	O
,	O
which	O
,	O
in	O
turn	O
,	O
can	O
lead	O
to	O
the	O
development	O
of	O
taste	O
disturbances	O
such	O
as	O
dysgeusia	O
.	O

Awareness	O
of	O
encephalitis	other-disease
is	O
raised	O
through	O
events	O
such	O
as	O
World	O
Encephalitis	other-disease
Day	O
which	O
was	O
founded	O
by	O
the	O
Society	O
in	O
2014	O
and	O
through	O
fundraising	O
events	O
.	O

Levodopa	O
has	O
been	O
reported	O
to	O
improve	O
symptoms	O
in	O
patients	O
with	O
Parkinson	other-disease
’	other-disease
s	other-disease
disease	other-disease
and	O
progressive	O
supranuclear	other-disease
palsy	other-disease
.	O

In	O
a	O
monogamous	O
couple	O
,	O
a	O
seronegative	O
female	O
runs	O
a	O
greater	O
than	O
30	O
%	O
per	O
year	O
risk	O
of	O
contracting	O
an	O
HSV	other-disease
infection	O
from	O
a	O
seropositive	O
male	O
partner	O
.	O

Permanent	other-disease
junctional	other-disease
reciprocating	other-disease
tachycardia	other-disease
(	O
PJRT	other-disease
)	O
is	O
a	O
rare	O
cardiac	O
arrhythmia	O
.	O

Because	O
medications	O
have	O
been	O
linked	O
to	O
approximately	O
22	O
%	O
to	O
28	O
%	O
of	O
all	O
cases	O
of	O
dysgeusia	other-disease
,	O
researching	O
a	O
treatment	O
for	O
this	O
particular	O
cause	O
has	O
been	O
important	O
.	O

Chronic	other-disease
kidney	other-disease
disease	other-disease
is	O
commonly	O
associated	O
with	O
sleep	O
symptoms	O
and	O
excessive	O
daytime	O
sleepiness	O
.	O

Specifically	O
,	O
common	O
side	O
effects	O
include	O
difficulty	O
becoming	O
aroused	O
,	O
lack	O
of	O
interest	O
in	O
sex	O
,	O
and	O
anorgasmia	other-disease
(	O
trouble	O
achieving	O
orgasm	O
)	O
.	O

This	O
is	O
associated	O
with	O
poorer	O
asthma	other-disease
control	O
.	O

The	O
young	O
director	O
succumbed	O
to	O
Spanish	other-disease
Influenza	other-disease
and	O
died	O
later	O
that	O
year	O
;	O
October	O
23	O
,	O
1918	O
,	O
at	O
the	O
age	O
of	O
28	O
.	O

He	O
died	O
on	O
March	O
17	O
,	O
2020	O
at	O
his	O
home	O
in	O
Winston-Salem	O
,	O
North	O
Carolina	O
of	O
kidney	other-disease
failure	other-disease
.	O

Systemic	other-disease
contact	other-disease
dermatitis	other-disease
(	O
SCD	other-disease
)	O
is	O
defined	O
as	O
a	O
dermatitis	other-disease
occurring	O
in	O
an	O
epi-cutaneously	O
contact-sensitized	O
person	O
when	O
exposed	O
to	O
haptens	O
systemically	O
such	O
as	O
orally	O
,	O
per	O
rectum	O
,	O
intravesically	O
,	O
transcutaneously	O
,	O
intrauterinely	O
,	O
intravenously	O
,	O
or	O
by	O
inhalation	O
.	O

``	O
Brucella	O
ceti	O
''	O
,	O
most	O
prevalent	O
in	O
dolphins	O
,	O
has	O
been	O
shown	O
to	O
cause	O
chronic	O
disease	O
,	O
increasing	O
the	O
chance	O
of	O
failed	O
birth	O
and	O
miscarriages	O
,	O
male	other-disease
infertility	other-disease
,	O
neurobrucellosis	other-disease
,	O
cardiopathies	other-disease
,	O
bone	O
and	O
skin	O
lesions	O
,	O
strandings	O
and	O
death	O
.	O

McCarter	O
died	O
in	O
Tampa	O
,	O
Florida	O
on	O
December	O
22	O
,	O
2015	O
,	O
at	O
the	O
age	O
of	O
52	O
from	O
the	O
genetic	O
liver	O
disorder	O
alpha	O
1-antitrypsin	O
deficiency	O
(	O
AAT	other-disease
)	O
.	O

This	O
causes	O
several	O
adverse	O
effects	O
,	O
including	O
hypotension	other-disease
and	O
cyanosis	other-disease
.	O

Trichotillomania	other-disease
alone	O
is	O
believed	O
to	O
affect	O
10	O
million	O
people	O
in	O
the	O
United	O
States	O
.	O

Vitamin	other-disease
B12	other-disease
deficiency	other-disease
causes	O
particular	O
changes	O
to	O
the	O
metabolism	O
of	O
two	O
clinically	O
relevant	O
substances	O
in	O
humans	O
:	O

In	O
Morocco	O
,	O
neonatal	other-disease
tetanus	other-disease
accounted	O
for	O
20	O
%	O
of	O
neonatal	O
deaths	O
in	O
1987	O
but	O
only	O
2	O
%	O
in	O
1992	O
.	O

The	O
availability	O
of	O
asparagine	O
is	O
also	O
important	O
for	O
protein	O
synthesis	O
during	O
replication	O
of	O
poxviruses	other-disease
.	O

Dysentery	other-disease
swept	O
through	O
the	O
camp	O
and	O
days	O
passed	O
between	O
the	O
instances	O
of	O
distribution	O
of	O
bread	O
to	O
some	O
.	O

Noncyclic	other-disease
acute	other-disease
wound	other-disease
pain	other-disease
is	O
intermittent	O
and	O
usually	O
occurs	O
during	O
procedures	O
such	O
as	O
sharp	O
debridement	O
.	O

A	O
meta-analysis	O
of	O
the	O
psychological	O
treatment	O
of	O
obesity	other-disease
in	O
children	O
and	O
adolescents	O
found	O
family-based	O
behavioral	O
treatment	O
(	O
FBT	O
)	O
and	O
Parent-Only	O
Behavior	O
treatment	O
to	O
be	O
the	O
most	O
effective	O
practices	O
in	O
treating	O
obesity	O
in	O
children	O
within	O
a	O
psychological	O
framework	O
.	O

However	O
,	O
these	O
physical	O
examination	O
findings	O
are	O
also	O
present	O
in	O
Valentino	other-disease
’	other-disease
s	other-disease
Syndrome	other-disease
.	O

Post-infectious	O
encephalitis	other-disease
tends	O
to	O
be	O
relatively	O
mild	O
,	O
whereas	O
post-infectious	O
encephalomyelitis	other-disease
has	O
a	O
case-fatality	O
rate	O
of	O
up	O
to	O
10	O
%	O
.	O

Typhoid	other-disease
fever	other-disease
is	O
one	O
of	O
Afghanistan	O
's	O
major	O
infectious	O
diseases	O
in	O
terms	O
of	O
food/waterborne	O
diseases	O
.	O

The	O
disorder	O
is	O
confined	O
to	O
the	O
penis	O
,	O
although	O
a	O
substantial	O
number	O
of	O
men	O
with	O
Peyronie	other-disease
's	other-disease
exhibit	O
concurrent	O
connective	O
tissue	O
disorders	O
in	O
the	O
hand	O
,	O
and	O
to	O
a	O
lesser	O
degree	O
,	O
in	O
the	O
feet	O
.	O

The	O
actor	O
had	O
Strabismus	other-disease
or	O
cross-eye	other-disease
problem	O
,	O
which	O
helped	O
him	O
get	O
comedic	O
roles	O
.	O

It	O
was	O
first	O
marketed	O
as	O
a	O
drug	O
to	O
treat	O
epilepsy	O
in	O
Switzerland	O
in	O
1963	O
under	O
the	O
brand	O
name	O
``	O
Tegretol	O
``	O
;	O
its	O
use	O
for	O
trigeminal	other-disease
neuralgia	other-disease
(	O
formerly	O
known	O
as	O
tic	other-disease
douloureux	other-disease
)	O
was	O
introduced	O
at	O
the	O
same	O
time	O
.	O

In	O
addition	O
to	O
the	O
genetic	O
associations	O
,	O
the	O
HLA	O
haplotype	O
A2B40	O
is	O
also	O
a	O
genetic	O
predisposition	O
to	O
PSP	other-disease
.	O

Pulmonary	O
arterial	O
hypertension	O
occurs	O
by	O
two	O
mechanisms	O
in	O
cardiac	other-disease
sarcoidosis	other-disease
:	O
reduced	O
left	O
heart	O
function	O
due	O
to	O
granulomas	O
weakening	O
the	O
heart	O
muscle	O
or	O
from	O
impaired	O
blood	O
flow	O
.	O

Hyperthermia	other-disease
differs	O
from	O
fever	O
in	O
that	O
the	O
body	O
's	O
temperature	O
set	O
point	O
remains	O
unchanged	O
.	O

This	O
effectively	O
divides	O
the	O
cataract	other-disease
into	O
four	O
quadrants	O
that	O
are	O
more	O
easily	O
removed	O
by	O
phacoemulsification	O
.	O

Although	O
Jenner	O
was	O
not	O
the	O
first	O
person	O
to	O
conceive	O
the	O
notion	O
of	O
cowpox	other-disease
protecting	O
against	O
the	O
smallpox	other-disease
virus	O
,	O
his	O
experiment	O
proved	O
the	O
theory	O
.	O

Acute	other-disease
ischemic	other-disease
stroke	other-disease
is	O
a	O
neurologic	O
emergency	O
that	O
may	O
be	O
reversible	O
if	O
treated	O
rapidly	O
.	O

Signature	O
9	O
has	O
been	O
identified	O
in	O
chronic	other-disease
lymphocytic	other-disease
leukemia	other-disease
and	O
malignant	other-disease
B-cell	other-disease
lymphoma	other-disease
and	O
feature	O
enrichment	O
for	O
T	O
&	O
gt	O
;	O
G	O
transversion	O
events	O
.	O

Anaphylactic	other-disease
shock	other-disease
can	O
be	O
provoked	O
in	O
allergic	O
persons	O
by	O
the	O
``	O
previous	O
''	O
use	O
of	O
latex	O
in	O
an	O
area	O
:	O
latex	O
is	O
typically	O
powdered	O
to	O
prevent	O
sticking	O
,	O
latex	O
proteins	O
become	O
attached	O
to	O
the	O
particles	O
of	O
powder	O
,	O
and	O
the	O
powder	O
becomes	O
airborne	O
when	O
the	O
latex	O
item	O
is	O
used	O
,	O
triggering	O
potentially	O
life-threatening	O
Type	O
I	O
reactions	O
when	O
the	O
latex-contaminated	O
powder	O
is	O
inhaled	O
by	O
susceptible	O
persons	O
.	O

Hypertrophic	other-disease
cardiomyopathy	other-disease
involves	O
enlargement	O
and	O
``	O
thickening	O
''	O
of	O
the	O
heart	O
muscle	O
.	O

Some	O
form	O
of	O
aphasia	other-disease
occurs	O
in	O
34	O
to	O
38	O
%	O
of	O
stroke	other-disease
patients	O
.	O

Although	O
7000	O
to	O
8000	O
new	O
cases	O
of	O
testicular	other-disease
cancer	other-disease
occur	O
in	O
the	O
United	O
States	O
yearly	O
,	O
only	O
400	O
men	O
are	O
expected	O
to	O
die	O
of	O
the	O
disease	O
.	O

Coached	O
by	O
former	O
NBA	O
player	O
Rick	O
Brunson	O
,	O
Wagner	O
Jr	O
.	O
helped	O
lead	O
Camden	O
to	O
25	O
consecutive	O
victories	O
before	O
the	O
team	O
's	O
season	O
was	O
ended	O
due	O
to	O
the	O
COVID-19	other-disease
pandemic	other-disease
.	O

Dysrhythmias	O
and	O
sudden	O
cardiac	O
death	O
(	O
SCD	other-disease
)	O
was	O
shown	O
to	O
occur	O
even	O
before	O
the	O
manifestation	O
of	O
DCM	other-disease
and	O
heart	O
failure	O
symptoms	O
in	O
LMNA	other-disease
mutation	O
carriers	O
.	O

Technically	O
speaking	O
,	O
schizotypal	other-disease
personality	other-disease
disorder	other-disease
may	O
also	O
be	O
considered	O
an	O
``	O
extended	other-disease
phenotype	other-disease
``	O
that	O
helps	O
geneticists	O
track	O
the	O
familial	O
or	O
genetic	O
transmission	O
of	O
the	O
genes	O
that	O
are	O
implicated	O
in	O
schizophrenia	other-disease
.	O

The	O
zonules	O
of	O
Zinn	O
are	O
difficult	O
to	O
visualize	O
using	O
a	O
slit	O
lamp	O
,	O
but	O
may	O
be	O
seen	O
with	O
exceptional	O
dilation	O
of	O
the	O
pupil	O
,	O
or	O
if	O
a	O
coloboma	other-disease
of	other-disease
the	other-disease
iris	other-disease
or	O
a	O
subluxation	other-disease
of	other-disease
the	other-disease
lens	other-disease
is	O
present	O
.	O

It	O
was	O
found	O
that	O
within	O
this	O
population	O
,	O
there	O
was	O
limited	O
education	O
and	O
even	O
if	O
the	O
Peruvian	O
men	O
knew	O
their	O
personal	O
risk	O
for	O
the	O
HIV	other-disease
infection	other-disease
,	O
they	O
were	O
not	O
more	O
likely	O
to	O
try	O
and	O
obtain	O
contraception	O
.	O

Also	O
,	O
a	O
condition	O
similar	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	other-disease
)	O
may	O
occur	O
in	O
patients	O
with	O
severe	O
Pneumocystis	other-disease
pneumonia	O
,	O
and	O
such	O
individuals	O
may	O
require	O
intubation	O
.	O

Diseases	O
that	O
appear	O
to	O
be	O
increased	O
in	O
Heterozygotes	O
are	O
Celiac	other-disease
Disease	other-disease
and	O
Type	other-disease
1	other-disease
Diabetes	other-disease
.	O

Although	O
what	O
causes	O
pedophilia	other-disease
is	O
not	O
yet	O
known	O
,	O
researchers	O
began	O
reporting	O
a	O
series	O
of	O
findings	O
linking	O
pedophilia	other-disease
with	O
brain	O
structure	O
and	O
function	O
,	O
beginning	O
in	O
2002	O
.	O

This	O
virus	O
is	O
quite	O
distinct	O
from	O
the	O
other	O
known	O
Hepatitis	other-disease
E	other-disease
viruses	other-disease
.	O

Teratogens	other-disease
such	O
as	O
stress	O
can	O
alter	O
prenatal	O
neural	O
development	O
,	O
leading	O
to	O
diminished	O
competence	O
after	O
birth	O
.	O

This	O
includes	O
allergic	other-disease
rhinitis	other-disease
(	O
hay	other-disease
fever	other-disease
)	O
and	O
hives	other-disease
.	O

there	O
is	O
no	O
specific	O
treatment	O
for	O
Nipah	other-disease
virus	other-disease
infection	other-disease
.	O

In	O
light	O
of	O
this	O
life-threatening	O
complication	O
,	O
all	O
suspected	O
cases	O
of	O
botulism	other-disease
are	O
treated	O
as	O
medical	O
emergencies	O
,	O
and	O
public	O
health	O
officials	O
are	O
usually	O
involved	O
to	O
identify	O
the	O
source	O
and	O
take	O
steps	O
to	O
prevent	O
further	O
cases	O
from	O
occurring	O
.	O

Cure	O
inveterate	other-disease
ulcers	other-disease
of	O
the	O
lips	O
or	O
any	O
other.	O
``	O

A	O
stress	other-disease
cough	other-disease
is	O
when	O
the	O
airways	O
of	O
the	O
throat	O
are	O
blocked	O
to	O
the	O
point	O
that	O
causes	O
a	O
reflexive	O
spasm	O
.	O

Many	O
dogs	O
and	O
cats	O
with	O
primary	O
adrenal	O
insufficiency	O
are	O
presented	O
in	O
Addisonian	other-disease
crisis	O
and	O
require	O
immediate	O
,	O
aggressive	O
therapy	O
.	O

This	O
explains	O
why	O
ferritin	O
levels	O
remain	O
relative	O
low	O
in	O
Hereditary	other-disease
hemochromatosis	other-disease
,	O
while	O
transferrin	O
saturation	O
is	O
high	O
.	O

c-Fos	O
has	O
also	O
been	O
identified	O
as	O
independent	O
predictor	O
of	O
decreased	O
survival	O
in	O
breast	other-disease
cancer	other-disease
.	O

It	O
is	O
classified	O
as	O
type	other-disease
II	other-disease
lupus	other-disease
nephritis	other-disease
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
.	O

Using	O
the	O
YP7	O
murine	O
monoclonal	O
antibody	O
,	O
GPC3	O
protein	O
expression	O
is	O
found	O
in	O
HCC	other-disease
,	O
not	O
in	O
normal	O
liver	O
and	O
cholangiocarcinoma	O
.	O

caused	O
by	O
gene	O
deletion	O
)	O
results	O
in	O
HNPP	other-disease
.	O

A	O
1998	O
MRI	O
study	O
of	O
nine	O
climbers	O
with	O
HACE	other-disease
clearly	O
demonstrated	O
vasogenic	O
edema	O
.	O

Most	O
cases	O
of	O
mumps	other-disease
deafness	O
affect	O
just	O
one	O
ear	O
and	O
are	O
temporary	O
,	O
but	O
permanent	O
hearing	O
loss	O
occurs	O
in	O
0.005	O
%	O
of	O
infections	O
.	O

Her	O
final	O
marriage	O
was	O
to	O
Sergei	O
Radzinsky	O
,	O
whom	O
she	O
married	O
to	O
keep	O
him	O
in	O
the	O
country	O
;	O
he	O
was	O
receiving	O
treatments	O
for	O
aplastic	other-disease
anemia	other-disease
as	O
a	O
result	O
of	O
exposure	O
to	O
Chernobyl	O
.	O

Obstructive	other-disease
sleep	other-disease
apnea	other-disease
or	O
sleep	other-disease
apnea	other-disease
is	O
defined	O
as	O
either	O
cessation	O
of	O
breathing	O
(	O
apnea	O
)	O
for	O
10	O
seconds	O
,	O
or	O
a	O
decrease	O
in	O
normal	O
breathing	O
(	O
hypopnea	O
)	O
with	O
an	O
associated	O
desaturation	O
in	O
oxygen	O
and	O
arousal	O
during	O
sleep	O
that	O
lasts	O
at	O
least	O
10	O
seconds	O
.	O

Loss	O
of	O
IL-2	O
can	O
thereby	O
contribute	O
to	O
the	O
development	O
of	O
autoimmunity	O
in	O
NOD	other-disease
mice	O
.	O

Physical	O
effects	O
of	O
teratogens	other-disease
are	O
common	O
,	O
but	O
endocrine	O
effects	O
are	O
harder	O
to	O
measure	O
.	O

Symptoms	O
of	O
ischemic	other-disease
colitis	other-disease
vary	O
depending	O
on	O
the	O
severity	O
of	O
the	O
ischemia	O
.	O

Intracranial	O
pressure	O
may	O
be	O
increased	O
due	O
to	O
medications	O
such	O
as	O
high-dose	O
vitamin	O
A	O
derivatives	O
(	O
e.g.	O
,	O
isotretinoin	O
for	O
acne	other-disease
)	O
,	O
long-term	O
tetracycline	O
antibiotics	O
(	O
for	O
a	O
variety	O
of	O
skin	O
conditions	O
)	O
and	O
hormonal	O
contraceptives	O
.	O

Akiyama	O
died	O
of	O
peritonitis	other-disease
in	O
1918	O
at	O
the	O
young	O
age	O
of	O
49	O
(	O
In	O
the	O
East	O
Asian	O
age	O
reckoning	O
,	O
it	O
is	O
sometimes	O
described	O
as	O
being	O
51	O
years	O
old	O
)	O
,	O
His	O
grave	O
is	O
at	O
Aoyama	O
Cemetery	O
in	O
Tokyo	O
.	O

It	O
is	O
also	O
used	O
in	O
Pulmonary	other-disease
Aspergillosis	other-disease
in	O
a	O
dry	O
powder	O
inhalation	O
system	O
.	O

It	O
causes	O
the	O
disease	other-disease
plague	other-disease
,	O
which	O
takes	O
three	O
main	O
forms	O
:	O
pneumonic	other-disease
,	O
septicemic	other-disease
,	O
and	O
bubonic	other-disease
.	O

The	O
appropriate	O
treatment	O
for	O
binocular	other-disease
diplopia	other-disease
depends	O
upon	O
the	O
cause	O
of	O
the	O
condition	O
producing	O
the	O
symptoms	O
.	O

The	O
genetic	O
conditions	O
such	O
as	O
Liddle	other-disease
's	other-disease
syndrome	other-disease
and	O
Congenital	other-disease
adrenal	other-disease
hyperplasia	other-disease
present	O
in	O
childhood	O
or	O
earlier	O
in	O
life	O
than	O
the	O
acquired	O
causes	O
which	O
can	O
present	O
at	O
any	O
age	O
.	O

MEITL	other-disease
is	O
only	O
1/5	O
to	O
1/10	O
as	O
common	O
as	O
EATL	other-disease
.	O

Gastroesophageal	other-disease
reflux	other-disease
disease	O
is	O
the	O
most	O
common	O
cause	O
of	O
heartburn	O
.	O

This	O
is	O
almost	O
exactly	O
matching	O
the	O
aberrant	O
splicing	O
pattern	O
seen	O
in	O
post-mortem	O
SZ	other-disease
patient	O
’	O
s	O
brains	O
.	O

A	O
Dry	other-disease
cough	other-disease
is	O
a	O
persistent	O
cough	O
where	O
no	O
mucus	O
is	O
present	O
,	O
this	O
can	O
be	O
a	O
sign	O
of	O
an	O
infection	O
.	O

However	O
,	O
hypotonia	other-disease
caused	O
by	O
cerebellar	other-disease
dysfunction	other-disease
or	O
motor	O
neuron	O
diseases	O
can	O
be	O
progressive	O
and	O
life-threatening	O
.	O

Complications	O
may	O
include	O
cellulitis	other-disease
or	O
poststreptococcal	other-disease
glomerulonephritis	other-disease
.	O

Noonan	other-disease
syndrome	O
with	O
multiple	O
lentigines	O
(	O
NSML	other-disease
)	O
which	O
is	O
part	O
of	O
a	O
group	O
called	O
Ras/MAPK	O
pathway	O
syndromes	O
,	O
is	O
a	O
rare	O
autosomal	O
dominant	O
,	O
multisystem	O
disease	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
protein	O
tyrosine	O
phosphatase	O
,	O
non-receptor	O
type	O
11	O
gene	O
(	O
``	O
PTPN11	O
``	O
)	O
.	O

Histone	O
acetyltransferases	O
(	O
HATs	O
)	O
and	O
HDACs	O
have	O
been	O
found	O
to	O
play	O
key	O
roles	O
in	O
genes	O
linked	O
to	O
diabetes	other-disease
.	O

Study	O
has	O
collected	O
wide-ranging	O
data	O
and	O
has	O
focused	O
on	O
risk	O
factors	O
that	O
predict	O
vascular	other-disease
disease	other-disease
,	O
diabetes	other-disease
,	O
cognitive	other-disease
impairmen	other-disease
t	O
and	O
dementia	other-disease
—	O
and	O
the	O
benefits	O
of	O
living	O
a	O
healthy	O
lifestyle	O
.	O

Low-set	O
ears	O
are	O
the	O
most	O
common	O
cranial	O
dysmorphism	O
seen	O
in	O
3C	other-disease
syndrome	other-disease
,	O
and	O
ocular	other-disease
coloboma	other-disease
is	O
the	O
least	O
common	O
of	O
the	O
non-concurrent	O
symptoms	O
(	O
cleft	other-disease
lip	other-disease
co-occurring	O
with	O
cleft	other-disease
palate	other-disease
is	O
the	O
least	O
common	O
)	O
.	O

Their	O
daughter	O
,	O
Caroline	O
Montgomery	O
Marriott	O
,	O
was	O
killed	O
by	O
the	O
Spanish	other-disease
Flu	other-disease
epidemic	O
in	O
1918	O
.	O

In	O
September	O
2017	O
the	O
US	O
FDA	O
approved	O
its	O
use	O
for	O
``	O
adult	O
patients	O
who	O
have	O
hormone	O
receptor	O
(	O
HR	O
)	O
-positive	O
,	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
-negative	O
advanced	O
or	O
metastatic	O
breast	other-disease
cancer	other-disease
that	O
has	O
progressed	O
after	O
taking	O
therapy	O
that	O
alters	O
a	O
patient	O
’	O
s	O
hormones	O
''	O
.	O

when	O
sick	O
with	O
tuberculosis	other-disease
in	O
December	O
1839	O
,	O
he	O
died	O
untimely	O
three	O
months	O
later	O

Diarrhea	other-disease
due	O
to	O
viral	O
agents	O
is	O
unaffected	O
by	O
antibiotic	O
therapy	O
,	O
but	O
is	O
usually	O
self-limited	O
.	O

The	O
FDA	O
granted	O
orphan	O
drug	O
designation	O
for	O
Hodgkin	other-disease
's	other-disease
lymphoma	other-disease
in	O
2004	O
.	O

Washington	O
State	O
tourist	O
guides	O
in	O
the	O
1920s	O
referred	O
to	O
Soap	O
Lake	O
as	O
the	O
``	O
world	O
's	O
greatest	O
mineral	O
sea	O
''	O
and	O
people	O
afflicted	O
with	O
Buerger	other-disease
's	other-disease
disease	other-disease
found	O
that	O
bathing	O
in	O
the	O
lake	O
would	O
cure	O
their	O
illnesses	O
.	O

Strabismus	other-disease
may	O
also	O
be	O
classified	O
based	O
on	O
time	O
of	O
onset	O
,	O
either	O
congenital	O
,	O
acquired	O
,	O
or	O
secondary	O
to	O
another	O
pathological	O
process	O
.	O

HIV	other-disease
enters	O
host	O
cells	O
in	O
the	O
blood	O
by	O
attaching	O
itself	O
to	O
receptors	O
on	O
the	O
surface	O
of	O
the	O
CD4+	O
cell	O
.	O

Decreases	O
in	O
GFAP	O
expression	O
have	O
been	O
reported	O
in	O
Down	other-disease
's	other-disease
syndrome	other-disease
,	O
schizophrenia	other-disease
,	O
bipolar	other-disease
disorder	other-disease
and	O
depression	other-disease
.	O

Injections	O
are	O
most	O
commonly	O
used	O
on	O
patients	O
having	O
been	O
exposed	O
to	O
hepatitis	other-disease
A	other-disease
or	O
measles	other-disease
,	O
or	O
to	O
make	O
a	O
kidney	O
donor	O
and	O
a	O
recipient	O
compatible	O
regardless	O
of	O
blood	O
type	O
or	O
tissue	O
match	O
.	O

It	O
is	O
similar	O
to	O
the	O
ristocetin	O
cofactor	O
assay	O
but	O
has	O
the	O
added	O
benefit	O
in	O
that	O
it	O
helps	O
in	O
the	O
diagnosis	O
of	O
type	other-disease
2B/pseudo	other-disease
von	other-disease
Willebrand	other-disease
disease	other-disease
(	O
vWD	other-disease
)	O
and	O
Bernard–Soulier	other-disease
syndrome	O
because	O
it	O
uses	O
patient	O
's	O
live	O
endogenous	O
platelets	O
,	O
whereas	O
ristocetin	O
cofactor	O
assay	O
tests	O
the	O
function	O
of	O
only	O
the	O
vWF	O
and	O
not	O
the	O
platelets	O
.	O

Paralysis	other-disease
of	other-disease
respiratory	other-disease
muscles	other-disease
will	O
lead	O
to	O
death	O
in	O
a	O
considerably	O
shorter	O
time	O
.	O

Proceeds	O
from	O
the	O
song	O
's	O
went	O
to	O
Sanfilippo	O
Children	O
's	O
Foundation	O
,	O
a	O
not-for-profit	O
charity	O
that	O
dedicates	O
their	O
resources	O
to	O
progressing	O
clinical	O
research	O
into	O
the	O
effective	O
treatment	O
of	O
Mucopolysaccharidosis	other-disease
III	other-disease
,	other-disease
also	O
known	O
as	O
MPSIII	other-disease
or	O
Sanfilippo	O
Syndrome	O
.	O

Diagnosis	O
is	O
relatively	O
easy	O
when	O
all	O
the	O
symptoms	O
of	O
narcolepsy	other-disease
are	O
present	O
,	O
but	O
if	O
the	O
sleep	O
attacks	O
are	O
isolated	O
and	O
cataplexy	O
is	O
mild	O
or	O
absent	O
,	O
diagnosis	O
is	O
more	O
difficult	O
.	O

Complications	O
from	O
PSC	other-disease
-associated	O
cancers	O
account	O
for	O
40	O
%	O
of	O
deaths	O
from	O
PSC	other-disease
.	O

Thus	O
,	O
diarrhea	other-disease
can	O
be	O
categorized	O
into	O
secretory	other-disease
diarrhea	other-disease
,	O
an	O
excess	other-disease
of	other-disease
secretion	other-disease
,	O
or	O
osmotic	other-disease
diarrhea	other-disease
which	O
is	O
a	O
lack	O
of	O
absorption	O
.	O

Several	O
causes	O
have	O
been	O
speculated	O
,	O
including	O
a	O
capillary	other-disease
leak	other-disease
syndrome	other-disease
from	O
cytokine	O
release	O
from	O
the	O
differentiating	O
myeloid	O
cells	O
.	O

There	O
are	O
2	O
possibilities	O
to	O
evaluate	O
splenomegaly	other-disease
in	O
the	O
clinical	O
examination	O
:	O
percussion	O
and	O
palpation	O
.	O

Shurugwi	O
has	O
not	O
escaped	O
the	O
scourge	O
of	O
the	O
AIDS	other-disease
pandemic	O
with	O
many	O
of	O
its	O
youthful	O
people	O
succumbing	O
to	O
the	O
deadly	O
virus	O
.	O

Estimates	O
for	O
the	O
incidence	O
of	O
androgen	other-disease
insensitivity	other-disease
syndrome	other-disease
are	O
based	O
on	O
a	O
relatively	O
small	O
population	O
size	O
,	O
thus	O
are	O
known	O
to	O
be	O
imprecise	O
.	O

Alpha-fetoprotein	O
,	O
human	O
chorionic	O
gonadotropin	O
(	O
the	O
``	O
pregnancy	O
hormone	O
``	O
)	O
,	O
and	O
LDH-1	O
are	O
the	O
typical	O
tumor	O
markers	O
used	O
to	O
spot	O
testicular	O
germ	O
cell	O
tumors	other-disease
.	O

Usually	O
this	O
hypoglycemia	other-disease
can	O
easily	O
be	O
treated	O
with	O
more	O
frequent	O
feedings	O
or	O
medical	O
doses	O
of	O
glucose	O
.	O

Sleep	other-disease
apnea	other-disease
is	O
often	O
diagnosed	O
with	O
an	O
overnight	O
sleep	O
study	O
.	O

This	O
episode	O
is	O
considered	O
one	O
of	O
the	O
later	O
outbreaks	O
of	O
the	O
centuries-long	O
pandemic	O
of	O
bubonic	O
plague	O
that	O
began	O
with	O
the	O
Black	other-disease
Death	other-disease
.	O

The	O
symptoms	O
are	O
the	O
same	O
for	O
both	O
meningitis	other-disease
and	O
aseptic	other-disease
meningitis	other-disease
but	O
the	O
severity	O
of	O
the	O
symptoms	O
and	O
the	O
treatment	O
can	O
depend	O
on	O
the	O
certain	O
cause	O
.	O

The	O
hospital	O
offered	O
in-patient	O
treatment	O
for	O
children	O
up	O
to	O
the	O
age	O
of	O
three	O
,	O
diagnosed	O
as	O
premature	other-disease
,	O
malnourished	other-disease
or	O
dyspeptic	other-disease
.	O

Urinary	other-disease
incontinence	other-disease
and	O
gait	other-disease
apraxia	other-disease
are	O
also	O
not	O
uncommon	O
findings	O
.	O

Mark	O
Arnold	O
Wainberg	O
,	O
(	O
21	O
April	O
1945	O
–	O
11	O
April	O
2017	O
)	O
was	O
a	O
Canadian	O
HIV/AIDS	other-disease
researcher	O
and	O
HIV/AIDS	other-disease
activist	O
.	O

The	O
technique	O
became	O
,	O
and	O
remains	O
,	O
standard	O
practice	O
for	O
the	O
initial	O
management	O
of	O
small	other-disease
bowel	other-disease
obstruction	other-disease
in	O
the	O
context	O
of	O
previous	O
abdominal	O
surgery	O
.	O

Insomnia	other-disease
may	O
increase	O
racing	O
thoughts	O
and	O
those	O
effected	O
will	O
find	O
sleep	O
apnea	O
treatment	O
and	O
nasal	O
surgery	O
helpful	O
to	O
eliminate	O
their	O
racing	O
thoughts	O
.	O

Hampton	O
remained	O
active	O
until	O
a	O
stroke	other-disease
in	O
Paris	O
in	O
1991	O
led	O
to	O
a	O
collapse	O
on	O
stage	O
.	O

The	O
formation	O
of	O
coronary	other-disease
thrombosis	other-disease
generally	O
follows	O
the	O
same	O
mechanism	O
as	O
other	O
blood	O
clots	O
in	O
the	O
body	O
,	O
the	O
coagulation	O
cascade	O
.	O

The	O
Austrian	O
Federal	O
Railways	O
puts	O
a	O
quarter	O
of	O
its	O
staff	O
(	O
10,000	O
workers	O
)	O
on	O
short-time	O
work	O
in	O
response	O
to	O
the	O
coronavirus	other-disease
pandemic	O
.	O

CD36	O
interacts	O
with	O
a	O
number	O
of	O
ligands	O
,	O
including	O
collagen	O
types	O
I	O
and	O
IV	O
,	O
thrombospondin	O
,	O
erythrocytes	O
parasitized	O
with	O
``	O
Plasmodium	other-disease
falciparum	other-disease
``	O
,	O
platelet-agglutinating	O
protein	O
p37	O
,	O
oxidized	O
low	O
density	O
lipoprotein	O
and	O
long-chain	O
fatty	O
acids	O
.	O

Catatonia	other-disease
can	O
be	O
stuporous	O
or	O
excited	O
.	O

OCD	other-disease
is	O
sometimes	O
considered	O
an	O
anxiety	O
disorder	O
.	O

Use	O
of	O
these	O
drugs	O
has	O
been	O
associated	O
with	O
a	O
decrease	O
in	O
depression	other-disease
and	O
increased	O
functioning	O
in	O
social	O
and	O
work	O
environments	O
.	O

He	O
is	O
a	O
researcher	O
of	O
autoimmune	O
diseases	O
,	O
with	O
focus	O
on	O
antiphospholipid	other-disease
syndrome	other-disease
and	O
lupus	other-disease
.	O

Hypoglycemia	other-disease
in	O
newborns	O
with	O
BWS	other-disease
should	O
be	O
managed	O
according	O
to	O
standard	O
protocols	O
for	O
treating	O
neonatal	O
hypoglycemia	other-disease
.	O

On	O
6	O
May	O
2020	O
,	O
Eunice	O
moderated	O
an	O
online	O
webinar	O
for	O
Medecins	O
Sans	O
Frontieres	O
or	O
Doctors	O
without	O
Borders	O
titled	O
``	O
Live	O
Chat	O
on	O
COVID-19	other-disease
:	O
How	O
MSF	O
Responds	O
to	O
a	O
Pandemic	O
''	O
.	O

The	O
franchisee	O
retained	O
it	O
from	O
the	O
former	O
business	O
in	O
the	O
building	O
in	O
light	O
of	O
COVID-19	other-disease
pandemic	O
safe	O
practices	O
.	O

The	O
slightly	O
higher	O
preference	O
for	O
SSRIs	O
over	O
SNRIs	O
as	O
a	O
first	O
choice	O
for	O
treatment	O
of	O
anxiety	other-disease
disorders	other-disease
may	O
have	O
been	O
influenced	O
by	O
the	O
observation	O
of	O
poorer	O
tolerability	O
of	O
the	O
SNRIs	O
in	O
comparison	O
to	O
SSRIs	O
in	O
systematic	O
reviews	O
of	O
studies	O
of	O
depressed	O
patients	O
.	O

The	O
recurrence	O
of	O
rheumatic	other-disease
fever	other-disease
is	O
relatively	O
common	O
in	O
the	O
absence	O
of	O
maintenance	O
of	O
low	O
dose	O
antibiotics	O
,	O
especially	O
during	O
the	O
first	O
three	O
to	O
five	O
years	O
after	O
the	O
first	O
episode	O
.	O

If	O
mood	O
disorder	O
episodes	O
are	O
present	O
for	O
the	O
majority	O
and	O
residual	O
course	O
of	O
the	O
illness	O
and	O
up	O
until	O
the	O
diagnosis	O
,	O
the	O
patient	O
can	O
be	O
diagnosed	O
with	O
Schizoaffective	other-disease
Disorder	other-disease
.	O

It	O
has	O
a	O
similar	O
pathology	O
to	O
Sandhoff	other-disease
disease	O
and	O
Tay–Sachs	other-disease
disease	O
.	O

Linaclotide	O
is	O
used	O
to	O
treat	O
irritable	other-disease
bowel	other-disease
syndrome	other-disease
with	O
constipation	O
and	O
chronic	other-disease
constipation	other-disease
with	O
no	O
known	O
cause	O
.	O

Desquamative	other-disease
gingivitis	other-disease
is	O
a	O
descriptive	O
clinical	O
term	O
,	O
not	O
a	O
diagnosis	O
.	O

In	O
recognition	O
of	O
World	O
AIDS	other-disease
Day	O
on	O
December	O
1	O
,	O
2009	O
,	O
AIDS	other-disease
.gov	O
again	O
hosted	O
the	O
Facing	O
AIDS	other-disease
initiative	O
,	O
among	O
other	O
activities	O
.	O

On	O
April	O
2	O
,	O
Ayaka	O
's	O
diagnosis	O
of	O
Graves	other-disease
'	other-disease
disease	other-disease
was	O
made	O
public	O
.	O

Growth	other-disease
hormone	other-disease
deficiency	other-disease
(	O
GHD	other-disease
)	O
is	O
a	O
medical	O
condition	O
in	O
which	O
the	O
body	O
produces	O
insufficient	O
growth	O
hormone	O
.	O

During	O
his	O
leadership	O
at	O
WHO	O
he	O
notoriously	O
had	O
a	O
conflict	O
with	O
then	O
head	O
of	O
the	O
WHO	O
's	O
Global	O
Programme	O
on	O
AIDS	other-disease
(	O
GPA	O
)	O
,	O
Jonathan	O
Mann	O
,	O
which	O
resulted	O
in	O
Mann	O
's	O
resignation	O
.	O

Monkeypox	other-disease
as	O
a	O
disease	O
in	O
humans	O
was	O
first	O
associated	O
with	O
an	O
illness	O
in	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
(	O
formerly	O
Zaire	O
)	O
,	O
in	O
the	O
town	O
of	O
Basankusu	O
,	O
Équateur	O
Province	O
,	O
in	O
1970	O
.	O

In	O
1999	O
,	O
the	O
world	O
incidence	O
of	O
Hansen	other-disease
's	other-disease
disease	other-disease
was	O
estimated	O
to	O
be	O
640,000	O
.	O

The	O
precipitating	O
infections	O
that	O
may	O
lead	O
to	O
septic	O
shock	O
if	O
severe	O
enough	O
include	O
but	O
are	O
not	O
limited	O
to	O
appendicitis	other-disease
,	O
pneumonia	other-disease
,	O
bacteremia	other-disease
,	O
diverticulitis	other-disease
,	O
pyelonephritis	other-disease
,	O
meningitis	other-disease
,	O
pancreatitis	other-disease
,	O
necrotizing	other-disease
fasciitis	other-disease
,	O
MRSA	other-disease
and	O
mesenteric	other-disease
ischemia	other-disease
.	O

Mutations	O
of	O
Aire	O
gene	O
in	O
human	O
cause	O
a	O
rare	O
autoimmune	O
disorder	O
called	O
Autoimmune	other-disease
Polyendocrinopathy	other-disease
Candidiasis	other-disease
Ectodermal	other-disease
Distrophy	other-disease
(	O
APECED	other-disease
)	O
.	O
,	O
which	O
usually	O
manifests	O
in	O
combination	O
with	O
other	O
autoimmune	O
diseases	O
e.g	O
.	O

It	O
is	O
used	O
as	O
a	O
topical	O
cream	O
against	O
fungal	O
skin	O
infections	O
,	O
including	O
``	O
Trichophyton	other-disease
mentagrophytes	other-disease
``	O
,	O
``	O
T.	other-disease
rubrum	other-disease
``	O
,	O
``	O
Epidermophyton	other-disease
floccosum	other-disease
``	O
and	O
``	O
Candida	other-disease
albicans	other-disease
``	O
.	O

Shown	O
to	O
suffer	O
from	O
Reye	other-disease
's	other-disease
syndrome	other-disease
in	O
infancy	O
,	O
as	O
well	O
as	O
anorexia	other-disease
nervosa	other-disease
later	O
in	O
life	O
,	O
she	O
overcomes	O
both	O
with	O
the	O
significant	O
aid	O
of	O
her	O
family	O
.	O

Fungi	O
responsible	O
for	O
fungal	O
sinusitis	O
are	O
``	O
Aspergillus	other-disease
fumigatus	other-disease
``	O
(	O
90	O
%	O
)	O
,	O
``	O
Aspergillus	other-disease
flavus	other-disease
``	O
,	O
and	O
``	O
Aspergillus	other-disease
niger	other-disease
``	O
.	O

Cyclothymia	other-disease
,	O
known	O
today	O
as	O
cyclothymic	other-disease
disorder	other-disease
,	O
tends	O
to	O
be	O
underdiagnosed	O
due	O
to	O
its	O
low	O
intensity	O
.	O

The	O
organization	O
has	O
a	O
commitment	O
in	O
the	O
mentoring	O
of	O
young	O
researchers	O
,	O
and	O
is	O
dedicated	O
to	O
finding	O
cures	O
for	O
cancer	other-disease
and	O
cardiovascular	other-disease
diseases	other-disease
by	O
identifying	O
their	O
underlying	O
molecular	O
mechanisms	O
.	O

A	O
speech	other-disease
disorder	other-disease
known	O
as	O
stuttering	O
is	O
seen	O
to	O
be	O
associated	O
with	O
underactivity	O
in	O
Broca	O
's	O
area	O
.	O

Review	O
of	O
the	O
literature	O
indicates	O
that	O
around	O
50-70	O
%	O
of	O
patients	O
have	O
urinary	other-disease
retention	other-disease
(	O
CES-R	other-disease
)	O
on	O
presentation	O
with	O
30-50	O
%	O
having	O
an	O
incomplete	other-disease
syndrome	other-disease
(	O
CES-I	other-disease
)	O
.	O

The	O
most	O
consistent	O
aspect	O
of	O
therapy	O
in	O
CF	other-disease
is	O
limiting	O
and	O
treating	O
the	O
lung	O
damage	O
caused	O
by	O
thick	O
mucus	O
and	O
infection	O
,	O
with	O
the	O
goal	O
of	O
maintaining	O
quality	O
of	O
life	O
.	O

Potential	O
complications	O
and	O
side	O
effects	O
from	O
the	O
procedure	O
include	O
lip	O
and	O
chin	other-disease
hypoanesthesia	other-disease
,	O
seromas	other-disease
,	O
edema	other-disease
,	O
transient	O
dysphagia	O
and	O
aspiration	O
,	O
and	O
surgical	O
site	O
infection	O
.	O

Recently	O
described	O
syndromes	O
such	O
as	O
the	O
Brugada	other-disease
Syndrome	other-disease
may	O
give	O
clues	O
to	O
the	O
underlying	O
mechanism	O
of	O
ventricular	other-disease
arrhythmias	other-disease
.	O

BFRBs	other-disease
may	O
affect	O
at	O
least	O
1	O
out	O
of	O
20	O
people	O
.	O

Papillamitosis	other-disease
is	O
associated	O
,	O
as	O
has	O
been	O
mentioned	O
before	O
,	O
with	O
symptoms	O
and/or	O
clinical	O
signs	O
such	O
as	O
dilated	other-disease
superficial	other-disease
veins	other-disease
,	O
varicose	other-disease
veins	other-disease
and	O
changes	O
in	O
the	O
skin	O
.	O

These	O
partners	O
include	O
the	O
Greater	O
Boston	O
YMCA	O
,	O
Bird	O
Street	O
Community	O
Center	O
,	O
the	O
Watertown	O
Boys	O
and	O
Girls	O
Clu	O
b	O
,	O
and	O
Mass	O
General	O
Hospital	O
's	O
Aspire	O
program	O
for	O
children	O
with	O
Asperger	other-disease
's	other-disease
syndrome	other-disease
.	O

In	O
small	O
dosages	O
,	O
it	O
is	O
very	O
efficient	O
in	O
the	O
therapy	O
of	O
systemic	other-disease
lupus	other-disease
erythematosus	other-disease
,	O
autoimmune	other-disease
hemolytic	other-disease
anemia	other-disease
,	O
granulomatosis	other-disease
with	other-disease
polyangiitis	other-disease
,	O
and	O
other	O
autoimmune	O
diseases	O
.	O

Disruptions	O
in	O
the	O
plantar	O
fascia	O
's	O
normal	O
mechanical	O
movement	O
during	O
standing	O
and	O
walking	O
(	O
known	O
as	O
the	O
Windlass	O
mechanism	O
)	O
place	O
excess	O
strain	O
on	O
the	O
calcaneal	O
tuberosity	O
and	O
seem	O
to	O
contribute	O
to	O
the	O
development	O
of	O
plantar	other-disease
fasciitis	other-disease
.	O

Symptoms	O
generally	O
occur	O
at	O
the	O
age	O
of	O
40	O
,	O
and	O
are	O
often	O
accompanied	O
by	O
depression	other-disease
and	O
psychosis	other-disease
.	O

It	O
is	O
found	O
Anik	O
is	O
suffering	O
from	O
Brain	other-disease
Tumour	other-disease
and	O
he	O
is	O
admitted	O
to	O
hospital	O
for	O
treatment	O
under	O
surgeon	O
Dr	O
Ashok	O
Mukherjee	O
.	O

This	O
concept	O
was	O
exemplified	O
in	O
2007	O
when	O
a	O
California	O
woman	O
died	O
of	O
water	other-disease
intoxication	other-disease
in	O
a	O
contest	O
sanctioned	O
by	O
a	O
radio	O
station	O
.	O

Thalassemia	other-disease
prevalence	O
in	O
India	O
is	O
3-4	O
%	O
,	O
with	O
10,000	O
to	O
12,000	O
reported	O
thalassemia	other-disease
births	O
taking	O
place	O
every	O
year	O
.	O

The	O
patient	O
was	O
a	O
12-year-old	O
girl	O
with	O
rheumatic	other-disease
mitral	other-disease
stenosis	other-disease
.	O

Individuals	O
with	O
DIOS	other-disease
may	O
be	O
predisposed	O
to	O
bowel	other-disease
obstruction	other-disease
,	O
though	O
it	O
is	O
a	O
separate	O
entity	O
than	O
true	O
constipation	O
.	O

When	O
suspected	O
on	O
the	O
basis	O
of	O
the	O
clinical	O
presentation	O
or	O
physical	O
findings	O
,	O
the	O
diagnosis	O
of	O
GnRH	other-disease
insensitivity	other-disease
should	O
be	O
confirmed	O
biochemically	O
.	O

Primary	O
sclerosing	O
cholangitis	O
is	O
one	O
of	O
the	O
major	O
known	O
risk	O
factors	O
for	O
cholangiocarcinoma	O
,	O
a	O
cancer	O
of	O
the	O
biliary	O
tree	O
,	O
for	O
which	O
the	O
lifetime	O
risk	O
among	O
patients	O
with	O
PSC	other-disease
is	O
10-15	O
%	O
.	O

The	O
initial	O
Google	O
paper	O
stated	O
that	O
the	O
Google	O
Flu	other-disease
Trends	O
predictions	O
were	O
97	O
%	O
accurate	O
comparing	O
with	O
CDC	O
data	O
.	O

By	O
1975	O
,	O
resulting	O
from	O
several	O
serious	O
injuries	O
that	O
led	O
to	O
hospitalization	O
in	O
the	O
intensive	O
care	O
unit	O
,	O
Salvatore	O
was	O
cured	O
of	O
his	O
impulse	other-disease
control	other-disease
disorder	other-disease
that	O
was	O
the	O
root	O
cause	O
of	O
his	O
addiction	O
to	O
high	O
speed	O
.	O

Signs	O
of	O
a	O
nasal	O
TVT	other-disease
include	O
nasal	O
fistulae	O
,	O
nosebleeds	O
and	O
other	O
nasal	O
discharge	O
,	O
facial	O
swelling	O
,	O
and	O
enlargement	O
of	O
the	O
submandibular	O
lymph	O
nodes	O
.	O

Da	other-disease
Costa	other-disease
's	other-disease
syndrome	other-disease
is	O
named	O
for	O
the	O
surgeon	O
Jacob	O
Mendes	O
Da	O
Costa	O
,	O
who	O
first	O
observed	O
it	O
in	O
soldiers	O
during	O
the	O
American	O
Civil	O
War	O
.	O

The	O
family	O
grew	O
to	O
include	O
two	O
daughters	O
and	O
two	O
sons	O
by	O
1920	O
when	O
Isabel	O
died	O
in	O
the	O
Spanish	other-disease
Flu	other-disease
epidemic	O
.	O

Estrogen	O
esters	O
are	O
used	O
in	O
hormone	O
therapy	O
,	O
hormonal	O
contraception	O
,	O
and	O
high-dose	O
estrogen	O
therapy	O
(	O
e.g.	O
,	O
for	O
prostate	other-disease
cancer	other-disease
and	O
breast	other-disease
cancer	other-disease
)	O
,	O
among	O
other	O
indications	O
.	O

Apart	O
from	O
colony	other-disease
collapse	other-disease
disorder	other-disease
,	O
losses	O
outside	O
the	O
US	O
have	O
been	O
attributed	O
to	O
causes	O
including	O
pesticide	O
seed	O
dressings	O
,	O
using	O
neonicotinoids	O
such	O
as	O
Clothianidin	O
,	O
Imidacloprid	O
and	O
Thiamethoxam	O
.	O

In	O
contrast	O
with	O
hyp	other-disease
''	other-disease
er	other-disease
''	other-disease
hidrosis	other-disease
,	O
which	O
is	O
a	O
socially	O
troubling	O
yet	O
often	O
benign	O
condition	O
,	O
the	O
consequences	O
of	O
untreated	O
hypohidrosis	other-disease
include	O
hyperthermia	O
,	O
heat	O
stroke	O
and	O
death	O
.	O

The	O
causes	O
of	O
acquired	other-disease
antithrombin	other-disease
deficiency	other-disease
are	O
easier	O
to	O
find	O
than	O
the	O
hereditary	O
deficiency	O
.	O

After	O
a	O
major	O
public	O
health	O
effort	O
,	O
Uganda	O
in	O
2011	O
was	O
certified	O
as	O
having	O
eliminated	O
tetanus	other-disease
.	O

Beyond	O
that	O
,	O
however	O
,	O
clinicians	O
generally	O
treat	O
to	O
avoid	O
thrombosis	other-disease
.	O

Sickle	other-disease
cell	other-disease
anemia	other-disease
is	O
a	O
pleiotropic	O
disease	O
because	O
the	O
expression	O
of	O
a	O
single	O
mutated	O
HBB	O
gene	O
produces	O
numerous	O
consequences	O
throughout	O
the	O
body	O
.	O

Type	other-disease
2	other-disease
(	O
Dunnigan	O
Variety	O
,	O
FPL2	other-disease
)	O
is	O
the	O
most	O
common	O
form	O
and	O
is	O
due	O
to	O
mutations	O
in	O
the	O
LMNA	O
gene	O
.	O

The	O
distinction	O
between	O
bronchial	other-disease
asthma	other-disease
and	O
cardiac	other-disease
asthma	other-disease
is	O
especially	O
important	O
because	O
some	O
treatments	O
for	O
bronchial	other-disease
asthma	other-disease
,	O
including	O
inhalers	O
,	O
may	O
worsen	O
cardiac	other-disease
asthma	other-disease
or	O
cause	O
severe	O
heart	other-disease
arrhythmias	other-disease
.	O

The	O
differential	O
diagnosis	O
of	O
congenital	other-disease
hyperinsulinism	other-disease
is	O
consistent	O
with	O
PMM2-CDG	other-disease
,	O
as	O
well	O
as	O
several	O
syndromes	O
.	O

Several	O
standardized	O
test	O
batteries	O
exist	O
for	O
diagnosing	O
and	O
classifying	O
aphasias	other-disease
.	O

Correcting	O
hyponatremia	other-disease
too	O
quickly	O
can	O
lead	O
to	O
complications	O
.	O

Thrombocytopenia	other-disease
is	O
defined	O
as	O
the	O
drop	O
in	O
platelet	O
count	O
from	O
the	O
normal	O
range	O
of	O
150,000	O
–400,000	O
/	O
μL	O
to	O
a	O
count	O
lower	O
than	O
150,000	O
/	O
μL	O
.	O

If	O
a	O
hemoglobin	O
tests	O
shows	O
that	O
a	O
person	O
's	O
levels	O
are	O
below	O
normal	O
,	O
it	O
means	O
they	O
have	O
a	O
low	O
red	O
blood	O
cell	O
count	O
,	O
which	O
is	O
known	O
as	O
anemia	other-disease
.	O

Dive	O
history	O
as	O
recorded	O
by	O
a	O
personal	O
dive	O
computer	O
or	O
bottom	O
timer	O
can	O
indicate	O
a	O
probability	O
of	O
gas	O
bubbles	O
being	O
a	O
consequence	O
of	O
decompression	O
sickness	O
,	O
lung	O
overpressure	O
induced	O
arterial	other-disease
gas	other-disease
embolism	other-disease
or	O
an	O
artifact	O
of	O
post	O
mortem	O
recovery	O
decompression	O
.	O

Many	O
cases	O
of	O
spontaneous	O
abortion	O
may	O
be	O
described	O
in	O
the	O
same	O
way	O
as	O
maternal	O
transplant	O
rejection	O
,	O
and	O
a	O
chronic	O
insufficient	O
tolerance	O
may	O
cause	O
infertility	other-disease
.	O

Schistosomiasis	other-disease
is	O
an	O
infectious	O
disease	O
from	O
freshwater	O
parasites	O
,	O
carried	O
by	O
snails	O
.	O

In	O
1991	O
,	O
student	O
Jill	O
Stewart	O
started	O
IU	O
Dance	O
Marathon	O
in	O
honor	O
of	O
her	O
friend	O
,	O
Ryan	O
White	O
,	O
who	O
died	O
from	O
AIDS	other-disease
the	O
year	O
before	O
.	O

The	O
addition	O
of	O
GM3	O
to	O
bladder	other-disease
cancer	other-disease
cells	O
also	O
decreases	O
their	O
cell	O
adhesion	O
and	O
inhibits	O
tumor	O
growth	O
.	O

Elevated	O
free	O
copper	O
levels	O
exist	O
in	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
,	O
which	O
has	O
been	O
hypothesized	O
to	O
be	O
linked	O
to	O
inorganic	O
copper	O
consumption	O
.	O

Cyclopamine	O
is	O
under	O
investigation	O
as	O
a	O
possible	O
treatment	O
for	O
several	O
cancers	O
(	O
such	O
as	O
basal	other-disease
cell	other-disease
carcinoma	other-disease
and	O
medulloblastoma	other-disease
)	O
and	O
skin	other-disease
disorders	other-disease
(	O
such	O
as	O
psoriasis	other-disease
)	O
,	O
which	O
result	O
from	O
excessive	O
Hh	O
activity	O
.	O

Otitis	other-disease
externa	other-disease
may	O
be	O
acute	O
(	O
lasting	O
less	O
than	O
six	O
weeks	O
)	O
or	O
chronic	O
(	O
lasting	O
more	O
than	O
three	O
months	O
)	O
.	O

Rotumah	O
was	O
born	O
with	O
hemiplegia	other-disease
and	O
cerebral	other-disease
palsy	other-disease
.	O

Myocarditis	other-disease
and	O
pericarditis	other-disease
that	O
occur	O
as	O
a	O
result	O
of	O
mumps	other-disease
may	O
lead	O
to	O
endocardial	other-disease
fibroelastosis	other-disease
,	O
i.e	O
.	O

GFAP	O
levels	O
are	O
already	O
used	O
as	O
a	O
marker	O
of	O
neurologic	O
damage	O
in	O
adults	O
who	O
suffer	O
strokes	other-disease
and	O
traumatic	other-disease
brain	other-disease
injuries	other-disease
.	O

With	O
considerable	O
speech	O
therapy	O
rehabilitation	O
,	O
global	other-disease
aphasia	other-disease
may	O
progress	O
into	O
expressive	other-disease
aphasia	other-disease
or	O
receptive	other-disease
aphasia	other-disease
.	O

Since	O
Sandhoff	other-disease
disease	O
was	O
only	O
discovered	O
in	O
1968	O
,	O
there	O
are	O
years	O
the	O
disease	O
has	O
gone	O
undetected	O
because	O
of	O
misdiagnoses	O
.	O

Reductions	O
in	O
HbA	O
available	O
overall	O
to	O
fill	O
the	O
red	O
blood	O
cells	O
in	O
turn	O
leads	O
to	O
microcytic	other-disease
anemia	other-disease
.	O

Hyperglycemia	other-disease
is	O
also	O
a	O
common	O
side	O
effect	O
.	O

Mitochondrial	O
disorders	O
,	O
including	O
MERRF	other-disease
,	O
may	O
present	O
at	O
any	O
age	O
.	O

Most	O
of	O
these	O
hypoglycemic	other-disease
newborns	O
are	O
asymptomatic	O
and	O
have	O
a	O
normal	O
blood	O
glucose	O
level	O
within	O
days	O
.	O

from	O
Department	O
of	O
Rehabilitation	O
and	O
Mental	O
Health	O
Counseling	O
,	O
University	O
of	O
South	O
Florid	O
a	O
say	O
``	O
An	O
example	O
of	O
a	O
person	O
who	O
may	O
benefit	O
from	O
discovery	O
is	O
an	O
individual	O
with	O
autism	other-disease
.	O

Microscopically	O
there	O
are	O
epithelioid	other-disease
granulomas	other-disease
and	O
vasculitis	other-disease
in	O
the	O
subcutaneous	O
tissue	O
,	O
making	O
it	O
a	O
form	O
of	O
paniculitis	other-disease
.	O

Anisocoria	other-disease
is	O
the	O
condition	O
of	O
one	O
pupil	O
being	O
more	O
dilated	O
than	O
the	O
other	O
.	O

If	O
a	O
patient	O
scores	O
3	O
or	O
more	O
it	O
indicates	O
severe	O
pancreatitis	other-disease
and	O
the	O
patient	O
should	O
be	O
considered	O
for	O
transfer	O
to	O
ITU	O
.	O